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Epidemiology of inflammatory bowel disease
Inflammatory bowel disease (IBD) is an idiopathic chronic inflammation of the 
gastrointestinal tract and consists of two major types; Crohn’s disease and ulcerative 
colitis. The incidence and prevalence of IBD varies worldwide.1 Traditionally, the 
highest numbers are reported in Northern - and Western Europe and North America, 
but increasing incidence rates have been reported from previous low incidence and 
prevalence areas as Eastern Europe, South America, Asia and the Pacific region.2 An 
estimated 50,000 to 68,000 new cases of ulcerative colitis and 23,000 to 41,000 new 
cases of Crohn’s disease are diagnosed annually throughout Europe. Collectively 
approximately 3.6-3.7 million patients suffer from IBD worldwide.1, 3
The increasing trend in incidence and prevalence of IBD over the last decades and 
its emergence in developing countries suggests a role of the Western lifestyle in the 
pathogenesis.4 Moreover, epidemiologic data from migrant populations show that 
the incidence and prevalence  of IBD in non-white ethnic groups increases after 
migrating to another geographical area, indicating that genetic and environmental 
factors interact to determine risk for IBD early in life.1 
Clinical and pathological aspects of inflammatory bowel 
disease 
The peak age of onset of ulcerative colitis and Crohn’s disease is between 15 and 30 
years, while a second peak occurs between 60-80 years.5 Although both ulcerative 
colitis and Crohn’s disease are chronic inflammatory disorders of the gastrointestinal 
tract, there is a distinct clinical and pathological presentation. 
From a pathological perspective Crohn’s disease is characterized by transmural 
inflammation involving the entire gut wall, granuloma formation and a characteristic 
cobblestone appearance due to an intermittent pattern of diseased and healthy tissue. 
It can affect any part of the gastrointestinal tract. The most commonly affected 
site is the terminal ileum.5 The disease course is typified by a sequence of flare-up 
episodes and remissions of varying durations, and clinical patterns vary according to 
disease location and disease behavior (penetrating, stricturing, and nonpenetrating/ 
nonstricturing or inflammatory).1, 6 Clinically, key features of Crohn’s disease are 
(mild) diarrhea, (low-grade) fever, abdominal mass, signs of malnutrition, weight 
loss and episodes of right lower quadrant abdominal pain.5, 7 Progression of anatomic 
damage leads to development of penetrating or stricturing complications such as 
strictures, inflammatory masses, abscesses, and fistulae.1 The large majority  of patients 
with Crohn’s disease (70-80%) will require intestinal surgery within a disease course 
of 20 years.1 Even with the recent developments in medical and surgical treatment 
options, there appears to a slight but significant higher mortality in patients with 
Crohn’s disease.8
Ulcerative colitis is characterized by inflammation limited to the mucosa of the 
colon, usually involving the rectum with proximal extending. The clinical course is 
characterized by episodes of active and inactive disease, a pattern observed in 80-
90% of the patients.6
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Since the mucosa continues to be destroyed, subsequent development of frailty 
vascular granulation tissue and electrolyte and water loss through the mucosa occurs. 
Therefore, the major symptoms of ulcerative colitis are rectal bleeding and diarrhea. 
Other symptoms are crampy abdominal pain, passage of mucus and tenesmus. The 
severity of symptoms correlates with the extent of the disease.5
Apart from the predominant intestinal manifestations, approximately one-third of 
the patients with IBD develop extra-intestinal manifestations, including peripheral 
arthritis, erythema nodosum, aphthous ulcers, pyoderma gangrenosum, uveitis, 
spondylarthropathy, and primary sclerosing cholangitis.9, 10 
Pathogenesis
Despite intensive study, the etiology and pathogenesis of IBD is currently still 
unclear. It is commonly thought that IBD is caused by an inappropriate and 
continuing inflammatory response to gut microbiota (commensal bacteria) in 
genetically susceptible individuals.11, 12 Thus it involves interactions among immune, 
environmental and genetic factors, resulting in the induction of inflammation, 
subsequent development of mucosal lesions and repair.13 
Genetic factors
Twin studies have initially highlighted the importance of genetic involvement in 
the pathogenesis of IBD and showed that genetic susceptibility is more pronounced 
in Crohn’s disease compared to ulcerative colitis.14, 15 In the past decades, several 
susceptibility loci for IBD have been identified. More recently genome wide association 
studies (GWAS) have identified at least 71 risk loci in Crohn’s disease and 47 risk loci 
in ulcerative colitis, including 28 that are shared between both disease entities.11, 16, 
17 Many of the mutations found were in genes encoding recognition, processing and 
killing of microorganisms and the regulation of immune processes.13 The findings 
highlighted pathways which were identified before trough immunological studies 
(IL-23, TH17 cells) as well as new pathways such as autophagy (the ATG16L1 and 
IRGM genes),18, 19 the process in which cellular contents can be degraded by lysosomes 
to be recycled in order to provide nutrients.20 This mechanism also plays crucial roles 
in the immune system for elimination of potentially deleterious proteins, organelles 
and pathogens.21 
Most of the alleles identified by GWAS are relatively common (allele frequencies >5%) 
and have modest or low effects with odds ratios < 1.5.22 As a single genetic risk factor, 
only nucleotide binding oligomerization domain protein 2 (NOD2) has a meaningful 
contribution to Crohn’s disease risk given that homozygosity for NOD2 mutations is 
associated with a > 20-fold increased risk for Crohn’s disease in Caucasians.23, 24 The 
contribution of NOD2 mutations to the development of Crohn’s disease underlines 
the importance of the intestinal microbiota and innate mucosal defense in the 
pathogenesis of IBD. NOD2 acts as an intracellular pattern recognition receptor 
(PRR) recognizing muramyl dipeptide (MDP) which is a conserved structure in 
bacterial peptidoglycans.25 Genetic variants in NOD2 causes a deficiency to detect 
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MDP.26 Moreover, NOD2 is required for the expression of a subgroup of intestinal 
anti-microbial peptides and thus critical for regulation of bacterial immunity within 
the intestine.27 
The role of microbiota
The role of luminal bacterial contents in IBD is well-recognized, based on several 
observations.28 (I) Crohn’s disease and ulcerative colitis preferentially occur in the 
colon and distal ileum, which contain the highest intestinal bacterial concentrations; 
bacteria and fungi increase in both concentration and complexity from the proximal 
gastric and duodenal population of 102 – 103 aerobic organisms/gram luminal 
contents to 1011 – 1012 predominantly anaerobic bacteria/ gram in the cecum and 
colon.12 (II) Patients with Crohn's disease and their unaffected relatives have a 
different composition of the intestinal microbiota, and patients with IBD even have 
higher concentrations of mucosal bacteria compared with healthy controls.29, 30 (III) 
These observations accord with evidence from experimental animal models in which 
the animals are susceptible for developing intestinal inflammation. In example, the 
HLA-B27 transgenic rat, a well known model of chronic intestinal inflammation, 
develops spontaneous colitis in the presence of commensal intestinal bacteria, but 
remains disease free in the germfree state.31, 32 (IV) In clinical practice, diversion of 
fecal stream can prevent and treat Crohn’s disease and recurrence of inflammation is 
observed on restoration or exposure to faecal material.33-35 
Intestinal immune system
The intestinal immune system represents a complex network of different lymphoid and 
non-lymphoid cell populations and humoral factors.36 In IBD, the immune defense 
against intestinal microbes fails at two levels: the epithelial mucosal barrier, which is 
the first line of defense of the mucosal immune system is leaky and impaired,37-40 and 
the innate and acquired host immune responses towards the intestinal microbiota 
are altered.41 Traditionally, Crohn’s disease has been characterized as a T helper (TH) 
1 disease by producing large quantities of interferon-γ (IFN-γ) and tumor necrosis 
factor α (TNF-α) while ulcerative colitis seemed to exhibit a TH2-type cytokine 
profile by producing IL-4 and IL-13.42, 43 Recently, a third class of CD4+ positive cells 
producing IL-17 and therefore called ‘Th17 cells’ have been identified, which are 
thought to contribute to the pathogenesis of IBD.43-45 Expression of these cells has 
been observed in the gut of patients with Crohn’s disease46 and abundant production 
of IL-17 has been observed in inflamed mucosa of IBD patients.47
Environmental factors
Among the environmental factors possibly involved in the pathogenesis of IBD, 
smoking clearly affects the risk for developing Crohn’s disease.1 On the contrary, 
smoking reduces the risk for developing ulcerative colitis.48
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Treatment 
Since the etiology of inflammatory bowel disease is still unclear, causative therapy 
is not available. IBD is a lifelong disorder and medical and surgical therapy should 
therefore be focused on long term outcomes with the primary treatment goal to 
induce and to maintain remission in a safe and efficacious way, and restore normal 
bowel function.6, 49 
Conventional agents used in the medical therapy of inflammatory bowel disease 
consist of three different subgroups of drugs, derivates of 5-aminosalicylic acid 
(5-ASA), corticosteroids, and immunomodulatory agents such as azathioprine, 
6-mercaptopurine, methotrexate and cyclosporine. Increasing knowledge on the 
central role of tumor necrosis factor α (TNF-α) in the inflammation present in IBD,50-
54 led to the development and use of (monoclonal) antibodies targeting this cytokine, 
including infliximab and adalimumab, in the treatment of IBD.55-59 
In general, therapeutic recommendations for Crohn’s disease depend on age, disease 
location, disease severity, and disease-associated complications. A step up approach 
is generally recommended in which more powerful therapies are initiated as the 
severity of disease and refractoriness to therapy increases, as depicted in figure 1.1.60-
62 Treatment is initiated with agents as 5-ASA derivates, budesonide, or systemic 
corticosteroids, followed by continuous immunosuppressive regime. Following 
this approach, patients who are unable to obtain or remain in remission despite 
adequate treatment with immunosuppressive drugs, patients with intolerance to 
conventional treatment (i.e. corticosteroids and immunosuppressants) and patients 
with enterocutaneous fistulas not responding to conventional therapies, are eligible 
for treatment with anti TNF-α therapies.49
 
Figure 1.1 Step up approach depicted (adapted from ref 63)
 
 
Surgery 
Biologicals 
AZA/ 6-MP      MTX 
Prednisone                  Budesonide  
5-ASA           Antibiotics 
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The traditional step up approach has been challenged however following a study 
by D’Haens et al.64 This study compared the effectiveness of the traditional strategy 
with a top down approach that combined immunosuppression of infliximab and 
azathioprine as the initiating treatment in active Crohn’s disease patients naïve to 
glucocorticoids, antimetabolites, or infliximab. They demonstrated superiority of the 
top down approach for early induction of remission and reduction of corticosteroid 
use in patients who had been recently diagnosed with Crohn’s disease. Furthermore, 
a recent study showed that infliximab monotherapy or infliximab plus azathioprine 
combination therapy is superior to azathioprine alone in immunosuppressant naive 
patients to maintain corticosteroid free remission and obtain mucosal healing.65 This 
indicates, apart from other studies, that an accelerated use of immunosuppressants 
and anti TNF therapy will induce and maintain remission, reduce steroid use and 
promote mucosal healing. Mucosal healing is associated with better long-term 
disease outcomes (less hospitalization and abdominal surgery, reduced relapse 
rate, steroid free remission).66-68 As been pointed out in a recent review, managing 
IBD can be compared with a dance with familiar steps (i.e. mesalamine, steroids, 
immunomodulators, or anti-TNF therapy and surgery) but the timing and sequence 
of the steps creates the dance.69
Apart from pharmacological, non pharmacological interventions can play an 
important role in the treatment of IBD. Smoking is a risk factor for disease relapse after 
medically- or surgically-induced remission in patients with Crohn’s disease. It is also 
associated with the need for higher doses of corticosteroids and immunosuppressants, 
and should therefore be discouraged in patients.70-73 Moreover, one year of smoking 
cessation leads to a more benign Crohn’s disease course with lower relapse rates.74
Although the therapeutic benefits of medical therapy in IBD are of major 
importance, it is frequently offset by numerous side effects, including bone marrow 
suppression (methotrexate, thiopurines), hepatitis and pancreatitis (5-ASA derivates, 
methotrexate, thiopurines), fluid retention, fat redistribution, hypertension, 
hyperglycaemia, psycho-neurological disturbances, cataracts, adrenal suppression, 
growth failure in children, and osteonecrosis (corticosteroids).75 Therefore, effects 
and adverse effects should be balanced while determining the appropriateness of 
medical therapy in IBD. 
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Outline of this thesis
The main objective of this thesis was to evaluate whether the use of infliximab is an 
adequate treatment of inflammatory bowel disease (IBD) in view of both effects and 
safety . 
Specific themes were studied, aiming:
1. To evaluate the occurrence of serious events after the onset of infliximab treatment 
in patients with IBD, with a mean follow-up of 9 years (Chapter 2A & 2B). 
2. To evaluate the necessity of monitoring vital signs during infusion therapy with 
infliximab (Chapter 2C). 
3. To identify similarities and differences within international, national and local 
guidelines and additional consensus statements from the medical specialties 
currently using infliximab (Chapter 3), regarding:
 a. Indications for infliximab
 b. Dosage for initial and maintenance therapy  
 c. Monitoring of vital signs during infusion with infliximab
 d. Synergetic effects with concomitant medication use 
4. To evaluate the direct hepatotoxicity of infliximab as compared to conventional 
therapies used in the treatment of IBD (Chapter 4). 
A subsequent objective was to identify genetical susceptibility factors which might be 
associated with the development of inflammatory bowel disease.
Specific themes with regards to this objective were:
1. To study the relationship between a polymorphism in UGT1A1 and drug side 
effects in patients with IBD (Chapter 5).
2. To test the hypothesis that the functional DECTIN-1 c.714T>G (p.Y238X) 
polymorphism is associated with lower disease susceptibility or severity in IBD 
and to investigate the level of dectin-1 expression in inflamed and non-inflamed 
colon tissue of IBD patients (Chapter 6). 
3. To investigate the possible modulating effect of the functional COX-2 
polymorphisms -1195 A→G and -765G→C on the risk for development of IBD in 
a Dutch population (Chapter 7).
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Serious events with infliximab in patients with 
inflammatory bowel disease: a 9-year cohort 
study in the Netherlands
Drug Safety 2008; 31(12):1135-1144
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Martijn GH van Oijen
Dirk J de Jong
Department of Gastroenterology and Hepatology, Radboud University Nijmegen 
Medical Centre, Nijmegen, The Netherlands
The tumour necrosis factor-α inhibitor infliximab is incorporated in the treatment 
guidelines for patients with inflammatory bowel disease (IBD). However, concerns 
about serious adverse events such as infections, malignancies and death do exist. The 
aim of this study was to evaluate the occurrence of serious events with infliximab 
during 9 years in a single-centre cohort of patients with IBD. Consecutive patients 
(>18 years) with a proven diagnosis of IBD who started treatment for IBD with 
infliximab at our referral centre in the Netherlands, from June 1999 to October 
2007, were included. Infusion data were collected prospectively, medical records 
were reviewed retrospectively. All serious events were recorded and scored in the 
following categories: events leading to hospitalisation, infections, malignancies and 
death. Severity and possible relationship to the use of infliximab were assessed for 
every serious event. 147 patients (33% male, mean age first infusion 38 years, standard 
deviation = 12) received a total number of 1924 infusions (median per patient = 
10, range 1 - 70). A total of 89 patients (61%) were hospitalized during follow-up, 
involving a total of 300 hospitalizations. Of these, 60 hospitalizations (20%) were 
considered at least possibly related to the use of infliximab. In 21 hospitalizations, 
the occurrence of a serious infection was considered at least possibly related to 
infliximab. Of all hospitalized patients, 70 patients (79%) underwent 139 surgical 
procedures, of which 70 surgeries (50%) were gastrointestinal related. 9 patients 
(6%) developed malignancies during follow-up: 4 colorectal carcinomas, 1 carcinoid 
tumour with another primary signet-ring cell carcinoma of the small bowel, 1 breast 
cancer, 2 skin cancers and 1 superficial melanoma. During follow-up, 8 patients (5%) 
died: 6 as a result of malignancies, 1 patient as a result of a complication of short 
bowel syndrome and 1 patient due to unknown reasons. Patients who developed 
malignancies tended to have a longer disease duration than those who did not.
Clinicians prescribing biological therapies should be aware of the development of 
serious events in their patients. Thorough follow-up of all patients during treatment 
with infliximab is warranted. If infliximab is considered in patients with IBD not 
responding to conventional treatment, efforts to exclude other possible underlying 
causes for worsening of symptoms should be made. Careful prescribing and 
monitoring during follow-up remains necessary.
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Introduction 
Inflammatory bowel disease (IBD) affects the lives of millions of people in the 
developed countries. The two major types of inflammatory bowel disease are Crohn’s 
disease (CD) and ulcerative colitis (UC). It is commonly thought that inflammatory 
bowel disease is caused by an exaggerated immune response to commensal bacteria 
in genetic susceptible individuals.1,2 Therefore, targeting this immune response plays 
an important role in the therapy of inflammatory bowel disease. 
The chimeric (partly human, partly murine) monoclonal antibody infliximab 
(Remicade, Centocor, Malvern, PA) which targets tumour necrosis factor α (TNF- 
α) is incorporated in the treatment guidelines for patients with inflammatory 
bowel disease, based on positive results in randomized clinical trials.3-5 In short, 
patients who are unable to remain in remission despite adequate treatment with 
immunosuppressive drugs, patients with intolerance to conventional treatment (i.e. 
corticosteroids and immunosuppressant’s) and patients with enterocutaneous fistulas 
not responding to conventional therapies, are eligible for treatment with infliximab.6 
Besides its prescription for IBD, infliximab is prescribed in patients with other auto 
inflammatory diseases like rheumatoid arthritis, ankylosing spondylitis, psoriatic 
arthritis and plaque sporiasis. 
Despite the fact that infliximab has benefit in a certain population of IBD patients not 
responding to conventional therapies, concerns about  serious and potentially severe 
side effects do exist. Side effects of infliximab on the short term are known from 
clinical trials and cohort studies, such as (acute) infusion reactions and infections.7 
Clinical evidence is now emerging on long term safety and efficacy with infliximab. 
The use of infliximab is clearly associated with a increased risk of infection. Serious 
opportunistic infections; mycobacterium infections, pneumocystis jiroveci (carinii) 
pneumonia, pulmonary actinomycosis and others have been described after the use 
of infliximab, as a result of  suppression of T-cell mediated immunity.8-11 
Another point of concern in the use of biologicals in inflammatory bowel disease 
is the development of malignancies, especially lymphomas. In 2006, Bongartz et al. 
published a meta-analysis on the risk of malignancies in patients with rheumatoid 
arthritis treated with infliximab in randomised clinical trials.12 The outcome of this 
analysis showed a dose-related increased risk for the development of malignancies. 
Furthermore, the development of hepatosplenic T-cell lymphoma, a very rare subtype 
of peripheral T-cell non-Hodgkin lymphoma, in paediatric and young adult patients 
treated with infliximab has been described.13 Although it is unclear if infliximab 
plays a role in the pathogenesis of this lymphoma, clinicians prescribing infliximab 
in paediatric patients have been warned by the manufacturer to pay attention to 
possible development of this very rare lymphoma in their patients.
In this single centre cohort study we evaluated the occurrence of serious events after 
the onset of infliximab treatment of patients with IBD, with a follow-up of nine years. 
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Methods 
Patients
Consecutive patients (>18yrs) with a proven diagnosis of IBD who started treatment 
with infliximab from June 1999 through October 2007 at our centre were included in 
our study cohort. Our centre, The Department of Gastroenterology and Hepatology 
of the Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, 
is a IBD referral centre. Referred patients and paediatric patients who had received 
infliximab elsewhere by the time of first infusion, were excluded. The dose of 
infliximab administered was based on patient’s weight and adjusted to a dose of 5 mg/
kg bodyweight, given as a 2-hours intravenous infusion. Indications for treatment 
with infliximab were based on Dutch treatment algorithms by that time available.14,15
Serious events with infliximab
Infusion data and doses were collected prospectively and complete medical records 
were reviewed retrospectively over the study period. The following variables related 
to infliximab were recorded: indication for infliximab, dose, duration and co-
medication (corticosteroids and immune suppressants) and the treatment strategy 
(on demand versus scheduled maintenance treatment). At the time we started with 
administering infliximab, most patients were on an ‘on demand’ schedule. However, 
when evidence came available indicating that an on demand strategy was associated 
with the development of antibodies to infliximab,16 patients switched to a maintenance 
strategy. Furthermore, the phenotype according to the Montreal Classification,17 
gender, age at start of infliximab treatment, and prior use of medication within one 
year before starting administering infliximab for a period of at least three months 
were abstracted. 
Acute infusion reactions were defined as any adverse event occurring during infusion 
or within a period of two hours after infusion, and delayed infusion reactions as 
reactions occurring from 24 hours to 14 days after treatment with infliximab, 
according to Cheifetz et al.18 A serious event was defined as any unfavourable 
event since the start of infliximab, from one of the following categories: infections, 
malignancies and death. 
Hospitalisations, length of stay and surgical procedures were assessed from medical 
records and electronic patient records; subdivided into gastrointestinal related and 
other. Furthermore, events were scored for severity and likelihood of relationship to 
infliximab; grading of adverse events was performed by adapting the grading of the 
National Cancer Institure (NCI) Common Terminology Criteria for Adverse Events 
(CT-CAE, table 2.1).19 Assessment of causality was performed by using a modified 
WHO-Uppsala Monitoring Centre (UMC )scale of case causality assessment (table 
2.2).20 Scoring was performed by an experienced gastroenterologist (DJ) blinded for 
information that could lead to a patient’s identity.
All events during follow-up were graded by the NCI CT-CAE, and defined as related 
to the use of infliximab if causality was scored 3 (possible) or 4 (probable), following 
the modified WHO-UMC scale of case causality assessment as described in table 2.2.
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Table 2.1 Grading system of adverse events adapted from the National Cancer Institute 
Common Terminology Criteria for Adverse Events19
Grade Description No. of 
events
Events 
related to 
infliximab 
use [n (%)]a
0 No adverse event (absent) or within normal limits - -
1 Mild adverse event (minor; no specific medical inter-
vention; asymptomatic laboratory findings only; radio-
graphic findings only; marginal clinical relevance)
1 0 (0)
2 Moderate adverse event (minimal intervention; local 
intervention; noninvasive intervention)
73 18 (25)
3 Severe and undesirable adverse event (significant 
symptoms requiring hospitalization or invasive inter-
vention; transfusion; elective interventional radiologi-
cal procedure;  therapeutic endoscopy or operation)
216 46 (21)
4 Life-threatening or disabeling adverse event (compli-
cated by acute, life-threatening metabolic or cardio-
vascular complications such as circulatory failure, 
haemorrhage, sepsis. Life-threatening physiological 
consequences; need for intensive care or emergent in-
vasive procedure; emergent interventional radiological 
procedure, therapeutic endoscopy or operation)
23 18 (78)
5 Death related to adverse event 7 6 (86)
aEvents are defined related to the use of infliximab if causality was scored 3 (possible) or 4 
(probable), following the modified WHO Uppsala Monitoring Centre scale of case causality 
assessment as described in table 2.2 NA = not applicable.
Table 2.2 Modified WHO-Uppsala Monitoring Centre scale of case causality assessment.20
Grade Description
1 Unrelated: a causal relationship can be definitively excluded and another docu-
mented cause of the event is most plausible
2 Unlikely: a causal relationship is improbable and another documented cause of 
the adverse event is most plausible
3 Possible: a causal relationship is clinically/biologically plausible and there is a 
plausible time sequence between onset of the adverse event and administration of 
infliximab
4 Probable: a causal relationship is clinically/biologically highly plausible and there 
is a plausible time sequence between onset of the adverse event and administra-
tion of infliximab and there is a reasonable response on withdrawal
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Statistics 
Frequency tables were compiled describing characteristics of the included patients at 
the time of their first infusion with infliximab. The number of hospitalizations were 
analysed on a patient level, and defined as related to the use of infliximab if causality 
was scored 3 or 4. This procedure was repeated for both serious infection and surgery 
as the reason for hospitalization. All patients who were hospitalized, whether or not 
the occurrence of a serious infection was the main reason, were compared with regard 
to the treatment strategy (on demand vs scheduled maintenance) and the use of co-
medication, which was defined as use over a period of at least 6 months. Patients who 
developed malignancies during follow-up were compared with the remaining patients 
for disease severity (defined as presence of fistulas), duration of disease, cumulative 
dose of infliximab and the use of concomitant medication using Student’s t-test and 
Pearson’s chi-squared test. The annual mortality and infection rate was calculated by 
dividing the number of deceased patients or patients with infection by the duration 
of follow-up in years. All calculations were performed using SAS software (version 
8.2; SAS Institute Inc., Cary, NC, USA). All p-values calculated were two-tailed and 
the alpha level of significance was set at 0.05. 
Results 
Patients
A total of 147 patients (33% male) were included; baseline characteristics at time 
of first infusion with infliximab are given in table 2.3. At baseline, mean age was 38 
years (standard deviation = 12) with a mean disease duration of 16 years. Primary 
indication for treatment was luminal CD in 55 patients (37%), fistulizing disease in 
80 patients (54%), UC in 9 patients (6%) and indeterminate colitis in 3 patients (2%). 
Involvement of different parts of the intestinal tract was scored using the Montreal 
classification: in patients with CD it was limited to the small bowel in 26 patients 
(18%), ileocolonic in 63 patients (43%) and colonic in 42 patients (29%). A total 
number of 1924 infusions were given with a median per patient of 10 (range 1–70), 
over a median follow-up of 59 months (range 1–99). Patients were followed for a total 
of 674 patient years. Twenty-eight patients (20%) received infliximab for less than 6 
months.
Infusion reactions
A total number of 16 acute infusion reactions were seen in 12 patients (8%). When 
patients developed acute infusion reactions, infusion was discontinued and patients 
received intravenous corticosteroids and a selective histamine H1 antagonist 
(clemastine). Based on the clinical response to these agents, infliximab was re-
administered at a slower infusion rate and discontinued if symptoms reoccurred. The 
majority of acute infusion reactions occurred during the fifth and sixth infusions 
and most patients who developed acute infusion reactions were receiving scheduled 
maintenance therapy (figure 2.1). There were 12 delayed infusion reactions, occurring 
in 10 patients (7%).
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Table 2.3 Baseline characteristics of 147 patients with inflammatory 
bowel disease at start of infliximab treatment
Characteristic No of patients
Mean age, years (SD) 38 (±12)
Male gender (%) 49 (33)
Mean disease duration, years (range) 16 (0-41)
Indication for infliximab treatment (%)
luminal CD 55 (37)
fistulizing CD 80 (54)
UC 9 (6)
indeterminate colitis 3 (2)
Montreal classification CD (%)
ileum 26 (18)
colon 42 (29)
ileocolonic 63 (43)
ileum + isolated upper disease 1 (1)
colon + isolated upper disease 1 (1)
ileocolonic + isolated upper disease 4 (3)
only perianal disease 1 (1)
Montreal classification UC (%)
ulcerative proctitis 1 (1)
left-sided 3 (2)
pancolitis (extensive colitis) 5 (3)
Prior medicationa
5-aminosalicylic acid 66 (45)
corticosteroids 113 (77)
antibacterials 15 (10)
immunosuppressants 90 (61)
Concomitant medication at first infusion (%)
corticosteroids 102 (69)
immunosuppressants 93 (63)
aMedication had to be used over a period of at least 3 months during 
the previous year. CD = Crohn’s disease; UC = ulcerative colitis.
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Figure 2.1 Acute infusion reactions to infliximab. Patients were stratified according to their 
treatment regimen (on demand vs scheduled).
The overall median number of hospitalizations per patient was 2, ranging from 1-19. 
Of the hospitalizations at least possible related to infliximab, the median number 
per patient was 1 (range 1-6). Overall median length of stay was 7 days (range 1-70) 
and in the group with hospitalization at least possibly related to infliximab, it was 
8 days (range 1-48). In 57 hospitalizations (involving 36 patients), the occurrence 
of a serious infection was the main reason for hospitalization; in 21 patients (24%) 
this was considered at least possibly related to infliximab. The following infections 
were recorded: abscess (58%), gastroenteritis (16%), urinary tract infection (11%), 
pneumonia (5%), sepsis (9%) and not categorizable (5%). It should be noticed that 
some patients had multiple types of infection. The annual infection rate was 5%. Of 
all 89 hospitalized patients, 70 (79%) underwent 139 surgical procedures of which 70 
(50%) were gastrointestinal related. Most patients were hospitalised because of their 
disease. No significant differences were found regarding different treatment schedules 
(on demand vs scheduled) and between the different groups of co-medication, i.e. 
corticosteroids, immunosuppressant’s or both (table 2.4).
Malignancies
During follow-up, nine patients (6%) developed malignancies (table 2.5). Four 
colorectal carcinomas, one carcinoid tumour with another primary signet-ring cell 
carcinoma of the small intestine, one breast cancer, one basal cell carcinoma, one 
squamous cell carcinoma of the skin and one superficial melanoma were seen. All 
malignancies except one were judged at least possibly related to the use of infliximab 
(table 2.5). The relationship is unlikely in the case of a 56-year-old man with a 14-
year history of CD, who was hospitalized because of general deterioration, dyspnoea, 
diarrhoea and fatigue. Besides his CD, he had a history of ankylosing spondylitis 
and a Dukes BII colon tumour, which had been completely removed 14 years 
earlier. During his hospitalization he received three infusions with infliximab. Six 
days after being discharged, he was re-admitted to the hospital because of a massive 
gastrointestinal bleeding and died during an emergency operation. 
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At autopsy, an adenocarcinoma was seen in the ileorectal region, with invasion of the 
iliac vessels. Three patients continued infliximab after the diagnosis of malignancy. 
Besides patients with basal cell carcinoma and superficial melanoma, there was one 
patient with metastatic breast cancer. This 52-year-old woman had a history of severe 
fistulizing perianal CD for 26 years and was responding well to infliximab. When 
diagnosed with breast cancer, her treating physicians strongly advised her to stop 
further treatment. Despite that, she decided to continue treatment with infliximab 
with the argument that she would rather have a few good months with limited CD 
activity and a potentially reduced life expectancy, than having a few more months 
with both active perianal CD and breast cancer.
Patients who developed malignancies were compared with patients who did not develop 
malignancies; no significant differences were found in age of onset, concomitant 
medication and existence of fistulae. Patients who developed malignancies had 
received a median number of 17 infusions with infliximab, compared with a median 
number of 10 infusions in patients who did not. The cumulative dose of infliximab 
received, which has been associated with the development of malignancies, did not 
show significant differences either; the mean dose in the group with malignancies 
was 1540 mg (600 - 35000 mg) versus a mean of 2500 mg (300 - 21940 mg). However, 
a significant difference was seen in duration of disease (p < 0.01); patients with 
malignancies had a mean duration of disease of 29 years (± 7.3 years), compared with 
a mean duration of disease of 15 years (± 8.6 years), in patients who did not develop 
malignancies.
Table 2.4 Summary of concomitant medication and treatment strategy regarding hospitali-
zation and infection
Medication Hospitalizations Infections
no. of 
events 
(n = 300)
no. of 
patients 
(n = 89)
median 
no. of events 
per patient
no. of 
events 
(n = 57)
no. of 
patients 
(n = 36)
median no. 
of events 
per patient
No concomitant 
medication
6 3 2 4 3 1
Corticosteroids 33 10 3 5 4 1
Immunosup-
pressants
57 16 2 7 4 1
Combination 136 31 3 28 14 1
Unknown 2 1 2 1 1 1
<6 Mo of 
infliximab
66 28 2 12 10 1
Infliximab
on demand 177 44 2 38 20 1
scheduled 123 45 2 19 16 1
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Deaths
During follow-up, eight patients (5%) died: six as a result of malignancies (all patients 
with colorectal carcinomas, breast cancer or primary signet-ring cell carcinoma of 
the small intestine), one patient as a result of a complication of short bowel syndrome 
and for one patient the reason was unknown. The annual mortality was 1.2%.
Discussion
In our 9 years of single-centre experience a total of 147 patients with IBD received 
nearly 2000 infusions with infliximab. In 12 patients (8%) an acute infusion reaction 
was seen and 10 patients (7%) developed delayed infusion reactions. Our rate of 
acute infusion reactions on a patient level is comparable with reported rates in other 
studies.18 With regard to the development of acute infusion reactions, most treatment 
algorithms state that vital signs should be monitored during infusion.18,21 We recently 
showed that scheduled monitoring of vital signs during infusion neither indicated nor 
predicted development of acute infusion reactions.22 Sixty - one percent of all patients 
were hospitalized after the start of infliximab treatment during follow-up. In 14% of 
all patients, the main reason for hospitalization was an infection that was considered 
at least possibly related to the use of infliximab. Nine patients developed malignancies 
and subgroup analysis, comparing patients with and without malignancies, showed a 
significant difference in duration of disease. During follow-up, eight patients died, the 
majority as a result of malignancies. In large, controlled clinical trials of maintenance 
therapy with infliximab in patients with CD, the annual rate of serious infections with 
infliximab ranged from 4% to 4.6%.3,23 Our annual infection rate is comparable to 
these studies, but slightly higher than demonstrated by follow-up data from clinical 
practice, which showed an annual incidence of serious infections of 1.2 - 2.1%.24,25 The 
TREAT (The Crohn’s Therapy, Resource, Evaluation and Assessment Tool) registry, 
a large scale, ongoing, observational registry of patients treated for CD, showed no 
significant differences in serious infection between patients treated with infliximab 
and patients not treated with infliximab in the latest published evaluation.26 However, 
a recent case-control study showed that immunosuppressive medication such as 
corticosteroids, azathioprine/ mercaptopurine and infliximab, especially when used 
in combination, is associated with an increased risk of opportunistic infections in 
patients with IBD.27 
In our cohort, only those infections for which hospitalization was required were 
registered. As a consequence, we underestimated the true rate of infections in 
patients treated with infliximab. Furthermore, patients could be treated for less 
severe infections by their general practitioner. Since we reviewed the medical charts 
retrospectively, this information could not be reliably retrieved. 
Concerns do exist about the development of lymphomas in patients treated with 
infliximab. In our cohort, only solid tumours were found with the majority being 
colorectal cancer. Patients with IBD, especially patients with UC and to a lesser degree 
patients with CD, are at greater risk of developing colorectal cancer, depending on 
risk factors such as duration and severity of disease and simultaneous primary 
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sclerosing cholangitis.28 In our subgroup analysis comparing patients with and 
without malignancies (patients with malignancies being the group who contributed 
most to the number of patients who died during follow-up), only duration of 
disease was significantly different. Duration of colitis is a significant contributor in 
the development of colorectal cancer in patients with IBD.28 Besides patients with 
UC, patients with CD have an increased risk of developing colorectal cancer.29,30 A 
general consensus exists that the same contributing factors for colorectal cancer in 
patients with UC apply for patients with CD.30 In our cohort, a causal relationship 
between the use of infliximab and the development of solid tumours can not be 
made; the malignancies seem to be more related to underlying disease than to the 
use of infliximab. However, these malignancies developed at a relative young age. 
This indicates that careful monitoring of patients with IBD for signs which could be 
attributable to a malignancy, is necessary to detect serious events at an early stage.
One patient was treated with infliximab for worsening of gastrointestinal symptoms, 
which on retrospective investigation were found to be caused by colorectal cancer. 
Since IBD-related symptoms may have other causes such as malignancy, clinicians 
should consider a diagnostic work-up before starting treatment with infliximab. 
We retrospectively checked the medical records of the four patients who developed 
colorectal cancer with regard to endoscopies performed. None of the colorectal 
cancers was discovered during a previous colonoscopy or sigmoidoscopy. Three of 
four patients underwent at least two colonoscopies in the 3-year period before the 
colorectal cancer was diagnosed.
Another patient, who developed breast cancer, insisted on continuing treatment with 
infliximab. This is in line with a recent study by Johnson et al., which revealed that 
patients with CD are willing to accept an elevated risk of serious adverse events in 
exchange for clinical efficacy with regard to their disease.31
Our annual mortality rate of 1.2% is in accordance with previous double-blind clinical 
trials with infliximab and follow-up data from clinical trials, reporting incidences 
ranging from 0.7-1.3%3,23 and from 1.2 - 1.3%,24,25 respectively. However, as pointed out 
by Lichtenstein et al.,26 this mortality rate is in accordance with published mortality 
rates in historical cohort studies before infliximab was introduced, with annual 
mortality rates of 1.3% in patients with CD.32,33 In the multivariate regression analysis 
of the TREAT registry, only the use of prednisone was an independent predictor of 
both serious infection and death.26 Our study was underpowered to perform such an 
extensive multivariate analysis. 
The use of infliximab in fistulizing CD is associated with a reduced number and 
length of hospitalizations.34 In our cohort, a considerable number of patients 
were hospitalised (61%) and 70 gastrointestinal surgeries were performed during 
follow-up. In our centre, infliximab given in a conventional ‘step-up’ approach was 
administered relatively late in the course of disease. This possibly had consequences 
for the biological behaviour of the disease, with progression of stricturing and fistula 
formation. It seems that this approach is not able to substantially change the course 
of disease and surgery remained inevitable in a large number of patients.
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One limitation of this study is the lack of a comparator, for example, a group of pa-
tients with similar disease severity, medication use, duration of disease and number 
of bowel segments involved but not treated with infliximab. As a consequence we 
can not report ‘higher rates’, but only high rates. Furthermore, no risk ratios could 
be calculated. Other factors such as concomitant use of corticosteroids and immune 
suppressants could likely contribute to the reported event rate here. Therefore, the 
reported adverse effects might be caused by conventional medication used together 
with infliximab. As conventional medication causes serious events as well,35 it is 
difficult to differentiate. Another limitation with regard to this retrospective study 
is that we were not able to differentiate between patients who fully responded to 
infliximab therapy and those who responded only partially or in whom response 
was lost, since response to infliximab was not measured prospectively following a 
standard protocol and definitions. 
While long term data on other TNF-α blocking agents used in the treatment of 
inflammatory bowel disease (e.g. adalimumab) are lacking, infliximab is the only 
TNF-α inhibitor suitable for long term safety analysis at this moment. Therefore, no 
comparison in long-term safety can be made. Although not studied in head-to-head 
trials, we would stress precautions concerning other anti TNF-α agents used in the 
treatment of inflammatory bowel disease as well.
Conclusion
Although infliximab is of great value in the treatment of IBD, clinicians prescribing 
biological therapies should be aware of the development of serious events in their 
patients. There might be an indication for surveillance screening for colorectal can-
cer in this subset of patients who are under infliximab treatment. Thorough follow-
up of these patients during treatment is warranted. If infliximab is considered in 
patients with IBD not responding to conventional treatment, efforts to exclude 
other possible underlying causes for worsening of symptoms should be made. 
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Safety of infliximab in inflammatory bowel 
disease needs to be debated
Clinical Gastroenterology and Hepatology 2009; 7(5):603-604
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Medical Centre, Nijmegen, The Netherlands
To the Editor,
With great interest we read the article by Caspersen et al. in which they investigated 
the long-term safety of infliximab in patients with inflammatory bowel disease (IBD) 
in a national Danish population-based cohort.1 They scored adverse events in up to 
47% of all patients and concluded that infliximab was generally well tolerated. Their 
conclusion based on these numbers is debatable, and is also based on a retrospective 
study, with subsequent non-standardized underreporting of adverse events as 
compared with prospective clinical trials. Moreover, the data of the Danish IBD 
cohort was gathered over a relatively short follow-up period.
In table 2.6, we compare their study with 3 other recently published retrospective 
cohort studies about the long-term safety of infliximab in patients with IBD from 
Belgium, Scotland, and The Netherlands.2-4  
Table 2.6 Characteristics of the Four Recently Reported Studies on the Long-Term Safety of 
Infliximab
Caspersen et 
al.1
Fidder et al.2 Lees et al.3 de Vries et 
al.4
Number of treated patients 651 734 202 147
Median age of starting 
therapy, years
31.6 (range, 
9.7-92.4)
35 (IQR, 
25-35)
30.8 (IQR, 
22.0-42.9)
38 (SD, 12)
Median disease duration 
before first infusion, years
5 (range, 
0-38)
7 (IQR, 
2-15)
4.9 (IQR, 
1.2-11.0)
16 (range, 
0-41)
Number of infusions 3351 7276 718 1941
Median number of infusi-
ons per patient
3 6 3 for CD, 1 
for UC
10
Follow-up period (patient- 
years)
- 3775 620 674
Median follow-up period, 
months
29.1 58 28.8 59
Number of infectionsa 69 
(63 patients)
59 
(48 patients)
60 
(42 patients)
57 
(36 patients)
Annual infection rate, % - 1.3% 7% 5%
Number of malignancies, % 4 (0.6) 21 (2.8) 6 (3.0) 9b (6.1)
Mortality, % 13 (2.0) 12 (1.6) 7 (3.5) 8 (5.4)
Annual Mortality rate, % - 0.3 1.1 1.2
IQR, interquartile range; CD, Crohn’s disease; UC, ulcerative colitis.
aIn one of the studies (de Vries et al), only those patients who underwent hospitalization 
for their infections were included. In others, hospitalization was not required in case of 
an infection. Therefore, the given numbers are not completely comparable since inclusion 
criteria are different between these studies.
bThere were 9 malignancies in 8 patients.
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The Denmark IBD population treated with infliximab developed fewer malignancies 
(4; 0.6%) compared with the cohorts from Belgium (21; 2.8%), Scotland (6; 3.0%), 
and The Netherlands (9; 6.1%). Most likely this could be explained by a relatively 
short follow-up period (median follow-up period, 29.1 months) compared with the 
cohorts from Belgium and The Netherlands (median follow-up periods, 58 and 59 
months, respectively), and therefore underestimation of the true rate of malignancies. 
The raised concern of developing malignancies in patients treated with anti–tumor 
necrosis factor, in combination with the fact that carcinogenesis is a process requiring 
many years of exposure to disease or treatment, makes it necessary to have a long 
term follow-up period to detect malignancies. This is emphasized further with the 
significant association with duration of disease and the development of malignancies 
in the studies from Belgium and The Netherlands. This indicates that thorough 
follow-up evaluation of patients with IBD for the development of malignancies is 
warranted. The question remains whether the high rate of malignancies is related to 
disease, treatment, or a synergistic effect. The Belgian cohort did include a control 
group of IBD patients treated in the same center and period. They compared IBD 
patients treated with infliximab with patients not receiving any biological therapy and 
found no differences in terms of mortality, infection rates, and malignancies.2 These 
findings need to be reproduced in other centers, but give us some first impressions 
regarding causality with IBD.
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Monitoring vital signs during infusion with 
infliximab does neither indicate nor predict 
development of acute infusion reactions
Journal of Clinical Gastroenterology 2009; 43(4):387-388
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Most treatment algorithms involving infliximab state that before and during infusion, 
vital signs [for example, mean arterial pressure (MAP) and pulse] should be monitored 
in case acute infusion reactions develop.1–3 Although easy to perform, monitoring and 
registering vital signs is time consuming and has consequences for the management 
of infusion units. In this era of increasing healthcare costs, nursing services should 
be appropriate to be cost effective.4 In the present study, we questioned the value of 
monitoring vital signs before and during infusion with infliximab on clinical relevant 
outcomes, that is, the development of acute infusion reactions. Consecutive patients 
with a proven diagnosis of inflammatory bowel disease (IBD) starting infliximab 
in the period June 1999 till October 2007 in the Radboud University Nijmegen 
Medical Center, Nijmegen, The Netherlands, a referral center for IBD, were included. 
Referred patients from other clinics who had received infliximab outside our clinic 
and pediatric patients (age < 18 years), by the time of first infusion, were excluded. 
The dose of infliximab administered was based on patient’s weight and adjusted to a 
dose of 5 mg/ kg bodyweight. Indications for treatment with infliximab were based 
on Dutch treatment algorithms available at that time.5,6
Vital signs (temperature, pulse, and blood pressure) were prospectively monitored 
before (baseline) and during all infusions on a structured datasheet and combined 
with clinical data on infusion reactions from medical files. We calculated mean 
arterial pressure (MAP) as follows: 
𝑀𝑀𝑀𝑀𝑀𝑀 = 1
3
 × (2 × 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 𝑏𝑏𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 𝑝𝑝𝑝𝑝𝑝𝑝𝑑𝑑𝑑𝑑𝑝𝑝𝑝𝑝𝑝𝑝 + 𝑑𝑑𝑠𝑠𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 𝑏𝑏𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 𝑝𝑝𝑝𝑝𝑝𝑝𝑑𝑑𝑑𝑑𝑝𝑝𝑝𝑝𝑝𝑝)  
  
 
Temperature was monitored by using a tympanic thermometer (Genius First Temp 
Model 3000A, Sherwood Medical, Sussex, United Kingdom). During an acute 
infusion reaction, time of onset, blood pressure, and pulse were measured and 
recorded on the same datasheet. Pearson’s w2 tests were used to find differences 
between patients with and without the experience of an acute infusion reaction for 
categorical variables, Fisher exact test was used where appropriate. Student t tests 
were used to analyze differences in continuous baseline characteristics. To adjust for 
multitesting, a 2-sided P value below 0.01 was regarded statistical significant. A total 
number of 151 patients (36% males) were included and received 1941 infusions. The 
median number of infusions per patient was 10 (range: 1 to 70). The overall incidence 
of acute infusion reactions to infliximab was 0.82% (17 of 1941 infusions), affecting 
13 patients (7.9%). Most documented symptoms were: dyspnea (41%), chest pain 
(41%), dizziness (35%), and flushing (18%). 
After developing an acute infusion reaction, 8 patients (62%) continued treatment 
and received consecutive infusions with IV corticosteroid and antihistamine 
prophylaxis. Of these, 3 patients (38%) experienced another acute infusion reaction. 
Baseline vital signs and body temperature between groups with and without acute 
infusion reactions were compared: MAP at baseline of the group with an acute 
infusion reaction (mean 88mm Hg±14) and pulse (mean 78 beats/min±9) compared 
with MAP (mean 88mm Hg±13) and pulse (mean 76 beats/min±13) in the group
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without an acute infusion reaction, showed no significant difference. Temperature 
at baseline in the group with an acute infusion reaction compared with the group 
without an acute infusion reaction did not show a significant difference (mean 36.9 
°C ± 0.47 compared with mean 36.8 °C ± 0.51). Subgroup analysis in 13 patients 
who experienced an acute infusion reaction showed no significant difference: MAP 
at baseline (mean 88 mm Hg ± 14) and pulse (mean 78 beats/ min ± 9) in infusions 
with an acute infusion reaction, and MAP (mean 83 mm Hg ± 14) and pulse (mean 
74 beats/ min ± 11) in infusions without an acute infusion reaction were measured, 
respectively. During an acute infusion reaction vital signs (mean MAP 90 mm Hg ± 
13 and mean pulse 77 beats/ min ± 9) did not show a significant change compared 
with the baseline of the group who experienced an acute infusion reaction (P = 0.7 
and 0.9, respectively). 
In conclusion, scheduled monitoring of vital signs during infliximab infusion did 
neither indicate nor predict development of acute infusion reactions in IBD patients 
and monitoring of vital signs during an acute infusion reaction did not show 
significant changes to baseline. Therefore, scheduled monitoring of vital signs
during infliximab infusions is not indicated in IBD patients. Our data are not a 
justification for more distant supervision of infusions, but indicate that infusion 
reactions are rather recognizable by clinical symptoms than by vital signs. This 
may lead to a more efficient allocation of nursing resources and will likely decrease 
healthcare costs and increase patient privacy and satisfaction.
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Infliximab, an anti-TNF biologic agent, is currently indicated and reimbursed 
for rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease (both adult and 
paediatric), ulcerative colitis, psoriatic arthritis and plaque psoriasis. Development 
of national and international guidelines for rheumatology, gastroenterology and 
dermatology, was mostly based on clinical studies and expert opinion. The aim of 
this study was to compare available guidelines and local protocols for rheumatology, 
dermatology and gastroenterology, regarding dosage of infliximab, synergy of 
infliximab with concomitant medication and monitoring of vital signs during 
infliximab administration, for achieving optimal care. Current international, 
national and local guidelines on the use of infliximab were reviewed and compared, 
differences and shortcomings were identified, and optimal treatment schedules 
discussed during a meeting (July 2008) of clinical experts and researchers from three 
departments of a Dutch university hospital. Recommended dosages of infliximab 
are not equal for different indications. Loss of response to infliximab is a common 
problem encountered within the three medical specialties, but indications for 
adjustments in treatment schedules are lacking in all of the guidelines. Monitoring 
of vital signs (blood pressure, pulse, temperature) during infusion with infliximab is 
common practice and recommended by some guidelines. Routine measurement of 
vital signs is not of any value in predicting or recognizing acute infusion reactions, 
in our experience, and this is confirmed by literature on inflammatory bowel disease. 
Different indications encompass different dosing schedules. National and internal 
guidelines do not provide advice regarding loss of response. Routine measurement of 
vital signs during infusion is not valuable in detecting acute infusion reactions and 
should only be performed in case of an acute infusion reaction. These topics need to 
be studied in future studies and covered in future guidelines.
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Introduction
Rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriatic arthritis, ankylosing 
spondylitis and psoriasis are chronic inflammatory diseases. Although the exact 
causes of these diseases remain unknown, over the past two decades major advances 
have been made in understanding the inflammatory processes. It is likely that in 
each of these diseases the innate and adaptive immune system are activated, with 
subsequent production of proinflammatory cytokines, like tumour necrosis factor 
alpha (TNF-α).1-3 Antibodies against TNF-α have been developed for the treatment 
of several chronic inflammatory diseases, including the monoclonal antibodies 
infliximab and adalimumab. Infliximab, a chimeric (partly human, partly murine) 
monoclonal antibody (biological), is the only intravenously administered anti-TNF 
antibody indicated and reimbursed for all of the following diseases: rheumatoid 
arthritis, ankylosing spondylitis, Crohn’s disease (both adult and paediatric), 
ulcerative colitis, psoriatic arthritis and plaque psoriasis.
National and international guidelines and consensus statements on the use of 
infliximab have been developed for each of the three medical specialties involved 
in treatment with infliximab (i.e. gastroenterology, rheumatology and dermatology) 
and reflect current use in clinical practice.
In many centres like ours, the care for patients receiving infliximab is combined 
for patients with autoinflammatory disorders. This emphasizes the need for a 
combination of guidelines for the treatment with infliximab for patients with these 
disorders within the involved medical specialities.
Methods
This paper is the product of an expert panel meeting, held by the authors in July 2008.
The purposes of this meeting were as follows:
•	 To identify similarities and differences within international, national and local 
guidelines and additional consensus statements from the medical specialties 
currently using infliximab as anti-TNF therapy, with regards to:
 - Indications for infliximab
 - Dosage for initial and maintenance therapy
 - Monitoring of vital signs during infusion with infliximab
 - Synergistic effects with concomitant medication use
•	 To discuss the following topics: optimal dosage of infliximab, monitoring of vital 
signs and use of concomitant medication.
•	 To discuss the optimal strategy in patients who have lost response to infliximab.
Members of the panel were selected, based on each member’s clinical and/or 
research experience with use of infliximab, from the departments of rheumatology, 
gastroenterology and dermatology from our university hospital. Members from each 
medical field performed a literature search in their own discipline by searching the 
MEDLINE database until July 2008, using the keyword ‘infliximab’, limiting their 
search to practical guidelines and consensus statements. 
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Additionally, the National Guideline Clearinghouse, a public resource for evidence-
based clinical practice guidelines of the Agency for Healthcare Research and Quality 
in the United States (http://www.guideline.gov) was searched on guidelines related 
to infliximab. In addition (local) Dutch guidelines from the medical specialties not 
accessible by MEDLINE but used in clinical practice were reviewed (for an overview 
of the reviewed guidelines and consensus statements see table 3.1). Regarding these 
guidelines and consensus statements, we limited ourselves to the previously identified 
topics, namely indication, dosage, monitoring, synergy and loss of response (i.e. 
secondary inefficacy). Results were presented and discussed during the panel meeting. 
Additionally, hiatuses within guidelines and consensus statements were discussed.
Results
Indication
Infliximab was first approved for patients with Crohn’s disease in 1998. Approval for 
other indications followed in the subsequent years (figure 3.1). In general, patients 
not responding to conventional therapy and having a moderate to high level of 
disease activity are eligible for treatment with a biological like infliximab.
Gastroenterology
Crohn’s disease patients with extra-intestinal manifestations and fistulizing disease 
are especially eligible for treatment with infliximab.4,5 Both the international 
consensus statements of the American Gastroenterological Association (AGA) and 
the European Crohn’s and Colitis Organisation (ECCO) as well as national guidelines 
agree that treatment with infliximab is appropriate for patients with inflammatory 
bowel disease experiencing corticosteroid dependency, glucocorticoid and/or 
immunomodulative treatment refractoriness or active fistula associated with Crohn’s 
disease.4, 6–8
Rheumatology
In rheumatoid arthritis, the international consensus statement on biologicals for 
the treatment of rheumatoid arthritis, which is updated nearly every year, does not 
provide criteria on which patients should be treated with antibodies against TNF-α, 
like infliximab.9 National guidelines however do provide such criteria. Patients 
should have failed on at least one (Swedish, French and Japanese guidelines) or two 
(British and Dutch guidelines) disease modifying anti-rheumatic drugs (DMARDs), 
including methotrexate in an adequate dosage and have a disease activity measured 
by the Disease Activity Score using 28 joint counts (DAS28)10 of > 5.1 (British 
guidelines).11–16 However, according to the Swedish guidelines no specific disease 
activity is required for starting with biologicals.15 The consensus statement of The 
American College of Rheumatology (ACR) recommends starting with anti-TNF 
therapy like infliximab in cases with 1) high disease activity (DAS28 > 5.1) for 3 - 6 
months, or 2) less than 3 months in combination with features of a poor prognosis 
(e.g. functional limitation, extra articular disease, rheumatoid factor positivity, 
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bony erosions by radiography) or 3) moderate disease activity (DAS28 > 3.2 and < 
5.1) for > 6 months and inadequate response to monotherapy with methotrexate in 
combination with features of poor prognosis.17
Figure 3.1 Approval by the US Food and Drug Administration (FDA) and 
the European Medicines Agency (EMEA) of infliximab (IFX). AS, ankylosing 
spondylitis; CD, Crohn’s disease; RA, rheumatoid arthritis, UC, ulcerative colitis; 
Ps, psoriasis; PsA, psoriatic arthritis. * Knight et al.62
Ankylosing spondylitis 
The international consensus statement from Furst et al. does not provide criteria 
for treatment with infliximab in patients with ankylosing spondylitis.9 However, 
another international consensus statement from the ASsessment in Ankylosing 
Spondylitis (ASAS) working group,18 as well as a statement from the Dutch Society 
for Rheumatology19 gives clear criteria on the use of infliximab in patients who 
fulfilled the modified New York criteria for the diagnosis of ankylosing spondylitis,20 
including active disease for > 4 weeks, (Bath Ankylosing Spondylitis Disease Activity 
Index (BASDAI) > 4 (0 - 10) and an expert opinion (the expert should consider 
clinical features (history and examination), serum acute phase reactant levels and/
or imaging results, such as radiographs demonstrating rapid progression or MRI 
indicating ongoing inflammation). 
Furthermore, all patients should have had adequate therapeutic trials of at least two 
NSAIDs, which is defined as: 
•	 Treatment for at least 3 months at maximum recommended or tolerated anti-
inflammatory dose unless contraindicated
•	 Treatment for < 3 months where treatment was withdrawn because of intolerance, 
toxicity or contraindications
The guideline from the French Society for Rheumatology (FSR) is more strict regarding 
co-medication, stating that patients should have failed at least three NSAIDs used for 
3 consecutive months while according to the guidelines from the British Society for 
Rheumatology (BSR) there should be a failure of conventional treatment with two or 
more NSAIDs, each taken sequentially at maximum tolerated/ recommended dosage 
for 4 weeks.21, 22 Although the guidelines from the BSR recommend treatment with 
infliximab, the British guidelines from the National Health Service (NHS) state that 
infliximab is not recommended for the treatment of ankylosing spondylitis.23
FDA approval for CD
FDA approval for RA
EMEA approval for CD
EMEA approval for RA
Development of IFX*
EMEA approval for AS
FDA approval for AS
EMEA approval for Ps
EMEA approval for PsA
FDA approval for UC
EMEA approval for UC
FDA approval for PsA
FDA approval for Ps
FDA approval for Pediatric CD
EMEA approval for Pediatric CD
1993 1995 1997 1999 2001 2003 2005 2007
US and European approval of infliximab for auto-inflammatory disorders
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Psoriatic arthritis 
As for rheumatoid arthritis and ankylosing spondylitis, the international consensus 
statement from Furst et al. does not provide criteria for treatment with infliximab 
in patients with ankylosing spondylitis.9 According to the NHS guidelines, 
patients with psoriatic arthritis are eligible for treatment with infliximab in case 
of peripheral arthritis with three or more tender joints and three or more swollen 
joints. Furthermore, the psoriatic arthritis has not responded to adequate trials of 
at least two standard DMARDs, administered either individually or in combination 
and the patient has been shown to be intolerant of, or have contraindications to, 
treatment with etanercept or has major difficulties with self administered injections.24 
The FSR guideline is more specific, indicating that the patient must have active and 
predominantly peripheral disease documented on two occasions at least 4 weeks 
apart, with both a tender joint count and a swollen joint count of 3 on a total of 76/78 
joints and have an overall assessment of disease activity by the physician of 4 on a 10 
point scale. Furthermore there should be persistent evidence of active disease after at 
least 4 months treatment with MTX in a dosage of 15 mg week-1, leflunomide 20 mg 
day-1, or sulfasalazine 2 g day-1.22
Dermatology
Few guidelines and consensus statements on the use of infliximab exist for patients 
with plaque psoriasis. According to the international consensus statement by Reich 
et al. patients with psoriatic arthritis in association with skin symptoms or moderate 
to severe psoriasis who have failed two or more systemic therapies are eligible for 
treatment with infliximab.25 Furthermore, patients with a Psoriasis Area and Severity 
Index (PASI) of 20 or patients with an improvement of less than 50% on this scale 
with previous (non) biological treatment, were eligible for treatment with infliximab.25 
The guideline of the British Association of Dermatologists (BAD) states that patients 
should have severe disease, defined as a PASI of 10 or more (or a body surface area of 
10% or greater where PASI is not applicable) and a Dermatology Life Quality Index 
>10. Secondly, patients should be unresponsive or intolerant to standard therapy.26 In 
the Netherlands, patients are eligible for biological therapies if they have a PASI of 10, 
and have failed to respond to phototherapy, methotrexate and ciclosporin in the past, 
or have a contraindication to, or are intolerant to these treatments.27
Dosage
The first randomized clinical trial with infliximab (at that time called cA2), in patients 
with rheumatoid arthritis, randomized patients over a single dose of 1 mg kg-1 
bodyweight, 10 mg kg-1 bodyweight and placebo.28 In this study, a dosage dependent 
response was observed. A subsequent study comparing the effect of multiple infusions 
with infliximab in patients with rheumatoid arthritis compared 1 mg to 3 mg and 10 
mg kg-1 bodyweight, showing the best results with the latter two.29 Furthermore it 
was shown that the median duration of response to the lowest dosage (i.e. 1 mg kg-1 
bodyweight) lasted 3 weeks, compared with 5 and 8 weeks with dosages of 3 and 10
Chapter 3 50
mg kg-1 bodyweight, respectively.30 Additional studies, performed in patients with 
Crohn’s disease, compared a single dose of 5 mg, 10 mg or 20 mg kg-1 bodyweight, 
administered over a 2 h period. In this trial, patients receiving 5mg kg-1 had the best 
response to infliximab.31 An open-label trial in Crohn’s disease patients, which was 
performed earlier, compared doses of 1 mg, 5 mg, 10 mg and 20 mg kg-1. The group 
receiving 1 mg kg-1 had a more transient response than the groups given the higher 
doses.32 One of the first case reports of psoriasis patients treated with infliximab 
reported a significant response with 5 mg kg-1 bodyweight and the first randomized 
trial in patients with psoriasis showed significant responses to 5 mg kg-1 and 10 mg 
kg-1 bodyweight.33, 34 
Gastroenterology
With regard to dosing of infliximab in inflammatory bowel disease, as can be seen in 
table 3.2, international and national consensus statement/guidelines recommend a 
dosage of 5 mg kg-1 body weight given in a 0-2-6-weeks induction regimen followed 
by maintenance dosing every 8 weeks.4, 7 The ECCO statement recommends the same 
dosage, since 5 mg kg-1 body weight has been shown effective in large placebo controlled 
trials.6, 35 However, this consensus statement gives no information regarding any 
induction regimen. According to the AGA consensus, primary non response can be 
determined after two doses.4 However, the Dutch guidelines recommend assessment 
of the treatment effect 8 weeks after the third infusion, when infliximab is combined 
with an immunosuppressant since immunosuppressants such as azathioprine and 
methotrexate only become effective after about 3 months.7 When the response is 
attenuated in patients, dosage can be increased to 10 mg kg-1 body weight or the 
interval between infusions can be shortened up to 4 weeks.6, 7
Rheumatology
In patients with rheumatoid arthritis, the standard dosage of infliximab administered 
recommended by most guidelines is 3 mg kg-1 bodyweight in an induction regimen at 
0, 2 and 6, and thereafter every 8 weeks.11, 13, 14 Some of the national and international 
guidelines do not explicitly state that infliximab should be administered at 3mg 
kg-1 bodyweight, but rather assume that clinicians will administer this ‘standard 
dosage’.9, 12, 17 As for patients with inflammatory bowel disease, if guidelines refer 
to attenuation of response, the dosage should be increased or the dosing interval 
shortened, together with the addition or substitution of another DMARD.9 The 
Japanese guideline, however, does not allow any increment of dosage or shortening 
of interval, and some guidelines do not give recommendations regarding this topic.12, 
14, 17 The National Institute for Clinical Excellence (NICE) guideline is most explicit 
in its recommendation, recommending increasing the dose of infliximab stepwise 
by approximately 1.5 mg kg-1, up to a maximum of 7.5 mg kg-1 every 8 weeks, or 
alternatively administering of 3 mg kg-1 as often as every 4 weeks.11 Recommended 
dosages from the reviewed guidelines and consensus statements regarding the specific 
diseases as well as the recommended dosage from the manufacturer are given in table 
3.2.
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Dermatology
The guidelines on the treatment of psoriasis with biologicals from the American 
Academy of Dermatology (AAD), BAD and the international consensus panel of 
dermatology experts advises dosing infliximab in a 5 mg kg-1 infusion schedule at 
0,2 and 6weeks, followed by maintenance treatment every 6 - 8 weeks (table 3.2).25, 
26, 36 The British guidelines however, state that no studies have been performed to 
establish the optimal dose or frequency of repeated infusions required in order to 
achieve disease control.26 The dermatology guidelines give no clear recommendation 
regarding how to manage attenuated response to infliximab (table 3.2).
Synergy
Repeated administration of infliximab has been associated with immunogenicity, i.e. 
the formation of antibodies to infliximab (ATI also known as HACA; human anti-
chimeric antibodies). The concomitant use of immunosuppressants may increase the 
efficacy of infliximab, partly because it prevents the development of immunogenicity, 
and partially by other mechanisms currently unknown.37–39 
Gastroenterology
The international ECCO guideline has been very clear and advocates that every 
patient receiving infliximab should receive an immunomodulator (i.e. azathioprine, 
methotrexate or 6-mercaptopurine) in order to prevent development of antibodies 
against infliximab that in turn may reduce efficacy and increase side effects.6 The 
consensus statement of the AGA strongly recommends co-administration with 
immunosuppressive therapy as well.4 The Canadian guidelines are most clear by 
recommending that all patients, even if they failed to respond to immunomodulators 
in the past, should receive concomitant immunosuppressants.8 The Dutch national 
guideline recommends initiation of immunosuppressants prior to infliximab in order 
to reduce the formation of antibodies.7
Rheumatology
Nearly all efficacy studies with infliximab in rheumatoid arthritis patients have 
been performed in patients receiving concomitant methotrexate.29 Therefore, all 
international, national and local guidelines recommend concomitant treatment with 
methotrexate in case of starting treatment with any anti TNF-α agent, including 
infliximab.13, 17
Dermatology
The AAD does not recommend concomitant prescription of low-dose methotrexate, 
although some dermatologists do so to decrease the formation of antibodies.36 The 
international consensus statement on the treatment of psoriasis with infliximab does 
not provide guidelines on the use of concomitant medication and the British guideline 
states that concomitant systemic therapies may be indicated for some patients with 
very severe or unstable psoriasis, although doses should be minimized.25, 26
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Monitoring of vital signs
As a foreign protein-derived agent administered intravenously over a 2 h infusion 
period, infliximab can cause infusion reactions. Formation of antibodies to 
infliximab may increase the risk of infusion reactions.37, 39 These infusion reactions 
can be categorized as acute or delayed. An acute infusion reaction is defined as any 
adverse event occurring during infusion or within a period of 24 h after infusion.37, 
40 Severity can vary from mild to severe life threatening, and symptoms may include 
nausea, flushing, dizziness, dyspnoea, chest pain and hypotension or hypertension. 
Delayed infusion reactions are defined as reactions occurring from 24 h to 14 days 
after treatment with infliximab and symptoms may include arthralgia, rash, myalgia 
and fatigue.37, 40 In randomized controlled trials with infliximab, vital signs (blood 
pressure, body temperature and pulse) were monitored vigorously. Monitoring body 
temperature at baseline is performed to rule out fever possibly based on infection 
and monitoring during infusion is performed while concerns exist about developing 
fever during an acute infusion reaction. The monitoring of blood pressure and pulse 
is based on the concern that during infusion with infliximab an anaphylactic shock 
could develop with typical hypotension.
Gastroenterology
Study protocols with infliximab in inflammatory bowel disease patients and some 
experts state that 30 min prior to, every 30 min during infusion and up till 2 h 
after infusion, vital signs (blood pressure, body temperature and pulse) should be 
monitored.41 Randomized controlled trials in patients with inflammatory bowel 
disease reported incidences of acute infusion reactions ranging from 9 - 17%.35, 42 In 
clinical practice the overall incidence of acute infusion reactions with infliximab is 
approximately 4 - 10%.40, 43 None of the international or national guidelines state that 
during infusion, vital signs should be monitored. However, in general it is common 
practice to monitor vital signs during infusion with infliximab.
Rheumatology and dermatology
As in gastroenterology, current practice in rheumatology and dermatology is to 
monitor vital signs of patients during infusion with infliximab. However, none of the 
guidelines give specific recommendations regarding monitoring of vital signs.
Interpretation
With the exception of patients treated for rheumatoid arthritis who are treated with a 
dosage of 3 mg kg-1 bodyweight, all patients who are treated with infliximab receive a 
dosage of 5 mg kg-1 bodyweight (table 3.2).To our knowledge, however, randomized 
controlled trials comparing response rates between 3 mg kg-1 or 5 mg kg-1 in patients 
with inflammatory bowel disease, rheumatoid arthritis or psoriasis have not been 
performed. Klotz et al. reviewed the current knowledge on clinical pharmacokinetics 
of infliximab and stated that little detailed information was available yet and was 
solely based on measurements of serum concentrations by ELISA using monoclonal 
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antibodies.44 Indeed, several studies in patients with rheumatoid arthritis, Crohn’s 
disease, ulcerative colitis, ankylosing spondylitis and psoriasis have shown that there 
is an interindividual variability of infliximab pharmacokinetics associated with 
an increase in clinical response with infliximab trough serum concentrations.45-49 
However, in these studies some patients showed good clinical response to infliximab 
with undetectable serum concentrations of infliximab. Indicating that the correlation 
between serum concentrations and clinical response is still imprecise. On the other 
hand, a small observational open label study in patients with rheumatoid arthritis 
routinely treated with infliximab, showed that the measurement of trough infliximab 
concentration modified the therapeutic decision for half of their patients and led to 
improved control of disease activity for patients for whom infliximab dosage was 
increased.50 Furthermore with regards to the pharmacokinetics of infliximab, the 
presence of ATI or HACA, which is associated with an increased risk of infusion 
reactions and a reduced duration of response, alter the pharmacokinetics of infliximab 
by an approximately 2.7 fold increase in systemic clearance.51 Taken together, these 
findings indicate that further investigations regarding the pharmacokinetics and 
pharmacodynamics of infliximab are warranted in order to individualize the dosage, 
based on at least the trough serum concentration and the existence of ATI. Thereby 
optimizing clinical response and cost effectiveness. 
Regarding attenuation of response, the guidelines of each specialty recommend 
dosage increase or interval shortening or changing to another biological therapy. 
However, there is no clear recommendation which option should be chosen in 
which subset of patients. Pharmacokinetic modelling of infliximab in patients with 
rheumatoid arthritis showed that interval reduction might be more effective in raising 
serum infliximab concentrations than dosage increase.46 Flendrie et al. observed in 
an open-label study a more pronounced efficacy in patients with rheumatoid arthritis 
receiving interval reduction, compared with patients receiving a dosage increase.52 
These observations need to be studied in large randomized trials. 
With the exception of ankylosing spondylitis, the need for concomitant administration 
of immunosuppressants during treatment with infliximab has been stressed by most 
of the guidelines throughout the different specialties, since it appears to prevent the 
development of antibodies against infliximab.37-39 However, benefits and risks of 
combined strategies should be balanced carefully as the evidence for increased risks 
of combined therapies is growing. This is most established for serious infections, 
which is observed in patients with inflammatory bowel disease.53, 54
Monitoring of vital signs during infusion with infliximab is based on strict regulations 
during clinical trials and still advocated in some treatment algorithms and guidelines.8, 
41 We recently showed that scheduled monitoring of vital signs during infusion did 
neither indicate nor predict development of acute infusion reactions.55 When baseline 
vital signs from patients with and without acute infusion reactions were compared, 
no significant differences were observed. Furthermore, during an acute infusion 
reaction, vital signs did not show a significant change compared with baseline.55 
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Conclusion
By reviewing current guidelines and consensus statements within the medical 
specialties of rheumatology, gastroenterology and dermatology on the use of 
infliximab for auto-inflammatory disorders, several topics (i.e. dosage of infliximab, 
monitoring of vital signs, use of concomitant medication and loss of response) were 
discussed and shortcomings in guidelines and consensus statements regarding these 
topics were identified. Based on this discussion, several recommendations have been 
made, as can be seen in table 3.3. Finally, as stressed by a recent quality appraisal of 
clinical practice guidelines and consensus statements on the use of biological agents 
in rheumatoid arthritis, guidelines should be explicit in their guidance,56 which has 
implications for the development of future guidelines.
Table 3.3 Conclusions and recommendations
Topics Conclusions and recommendations
Dosage of infliximab Based on several controlled clinical studies, certain 
standard dosage regimens for infliximab have been de-
fined which probably need some re-evaluation in terms 
of improving benefit: risk ratios.44
Future studies are needed to study the pharmacokine-
tic–pharmacodynamic relationship of infliximab as a 
necessary step before therapeutic drug monitoring can 
be recommended in guidelines.
Monitoring vital signs Routine scheduled measurement of vital signs during in-
fusion is not valuable in detecting acute infusion reacti-
ons and should only be performed in the case of an acute 
infusion reaction.55
We recommend to administer infliximab at an infusion 
unit under supervision of trained personnel. This appro-
ach enables direct interventions in case a patient reports 
symptoms. Baseline assessment of patients, including 
vital signs, should still be performed as normal clinical 
practice to rule out possible infections or other contrain-
dications for infusion with infliximab.
Use of concomitant medication Efforts should be made to establish a reasonable time 
interval in which concomitant medication should be 
decreased.
Loss of response to infliximab Although some evidence exists that interval reduction 
might be more effective in raising serum infliximab 
concentrations than dosage increase, large randomized 
trials are needed to observe whether or not interval 
reduction is superior to dosage increase. Furthermore, 
in which subset of patients in order to be able to give 
guidance regarding loss of response in clinical guideli-
nes.
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Infliximab-induced hepatotoxicity is reported in several case studies involving 
patients with inflammatory bowel disease (IBD) and a direct hepatotoxic effect has 
been proposed. The aim of this study was to determine the direct in vitro toxicity of 
infliximab. As a proof of principle the in vitro toxicity of thiopurines and methotrexate 
was also determined.
Cell survival curves and the half maximal inhibitory concentrations (IC50) were 
obtained after 24, 48 and 72 hours of incubation in HepG2 cells with the IBD drugs 
azathioprine, 6-mercaptopurine, 6-thioguanine, methotrexate or infliximab by using 
the WST-1 cytotoxicity assay. 
No in vitro hepatotoxicity was seen with infliximab, while concentration-dependent 
cytotoxicity was observed when HepG2 cells were incubated with increasing 
concentrations of azathioprine, 6-mercaptopurine and 6-thioguanine. Infliximab 
alone or given in combination with azathioprine showed no direct hepatotoxic effect 
in vitro, indicating that the postulated direct hepatotoxicity of infliximab is unlikely. 
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Introduction
Hepatotoxicity is defined as injury to the liver that is associated with impaired 
liver function caused by exposure to a drug or another noninfectious agent.1 It is a 
serious complication, frequently observed in the medical treatment of inflammatory 
bowel disease (IBD).2 It can be directly attributed to the type of drugs used to 
treat IBD, such as immunosuppressants or biological therapies targeting TNF-α. 
However, hepatotoxicity may also result from drugs used to treat complications 
of immunosuppressants and TNF-α antagonists, e.g. isoniazid for treatment of 
reactivation tuberculosis, or may be due to exacerbation of underlying chronic viral 
hepatitis caused by immunosuppression.3
In December 2004 the Food and Drug Administration (FDA) issued a drug warning 
to alert health care professionals on the risk of hepatotoxicity linked to infliximab.4 
However, severe hepatic reactions, including acute liver failure, jaundice, hepatitis or 
cholestasis have been rarely reported in patients receiving infliximab.5-8 Furthermore, 
as demonstrated by Sokolove et al. elevations of serum transamines in patients 
receiving biological therapy are uncommon and abnormalities of more than two 
times the upper limit of normal are rarely observed.6 The mechanism of infliximab-
induced hepatotoxicity is poorly understood, although a direct hepatoxic effect has 
been proposed by several authors.6-8 To our knowledge, no in vivo or in vitro results 
supporting this hypothesis have been reported.
The aim of this study was to determine the in vitro hepatotoxicity of infliximab. As 
a proof of principle, conventional IBD medication i.e. the thiopurines azathioprine, 
6-mercaptopurine and 6-thioguanine and methotrexate, which all are known to 
be hepatotoxic, were also tested. Although cultures of primary human hepatocytes 
seem to have the most relevant physiological properties for the evaluation of in vitro 
IBD drug hepatotoxicity, they are difficult to obtain and rapidly lose their metabolic 
properties.9 Therefore, we used a human liver hepatocellular carcinoma (HepG2) 
cell line, which is very stable, easy to handle and previously used in drug toxicity 
studies.9 HepG2 cells were incubated with increasing concentrations of infliximab, 
methotrexate or thiopurines for 24, 48 or 72 hours and subsequently cell viability was 
determined. 
Materials & Methods
Cell culture
Human hepatocellular carcinoma (HepG2)  cells (American Type Culture Collection, 
Rockville, Maryland, USA) were grown in Dulbecco’s Modified Eagle Medium 
(DMEM, PAA Laboratories GmbH, Pasching, Austria) containing 10% (v/v) heat-
inactivated fetal bovine serum (Gibco Invitrogen, Paisley, Scotland), 1X non-essential 
amino acids (PAA), 20mM HEPES buffer (PAA) and 50 mg/l gentamycin (Gibco) at 
37 0C in a humidified atmosphere containing 5% CO2. Medium was renewed every 
3 days and when confluence was reached, cells were harvested with trypsin/EDTA
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(Cambrex, Verviers, Belgium), washed with phosphate-buffered saline, and used for 
cytotoxicity assays. 
Cytotoxicity assays
HepG2 cells were seeded in flat-bottomed 96-well microtitre plates (Costar; Corning 
Inc., Corning, New York, USA) at a density of 5.0 x 104 cells per well in a final volume 
of 100 µl culture medium, and cells were cultured for 24 hours. Subsequently, cells 
were incubated with the single drugs azathioprine, 6-mercaptopurine, methotrexate 
(all Sigma-Aldrich Chemie B.V., Zwijndrecht, the Netherlands), 6-thioguanine (Alfa 
Aesar GmbH & Co KG, Karlsruhe, Germany) or infliximab (Remicade©, Centocor, 
Leiden, the Netherlands), for 24, 48 and 72 hours. The following concentration series 
were used; azathioprine: 0.002 µM - 4 mM; 6-mercaptopurine: 0.002 µM - 200 µM; 
6-thioguanine: 0.002 µM-4 mM; methotrexate: 50 nM-100 µM; infliximab: 0.002 
mg/l - 5 g/l. 
In subsequent experiment cytotoxicity of a combinations of drugs was tested. A 
single, non-toxic concentration of azathioprine (1µM) was tested in combination 
with a concentration range of infliximab (0.002 mg/l - 5 g/l), whereas a single, non-
toxic concentration of infliximab (312 mg/l) was tested in combination with a 
concentration range of azathioprine (0.002 µM - 4 mM).
All drugs were first dissolved in 0.1 M NaOH and then rapidly diluted in culture 
medium to reach the final concentration. Refreshment of culture medium with the 
various concentrations of drugs was done every 24 hours. After incubation with 
drugs, cell survival assessment was performed by adding water-soluble tetrazolium 
salt-1 (WST-1, Roche Diagnostics Nederland BV, Almere, the Netherlands) according 
to the manufacturer’s instructions. In the WST-1 assay, tetrazolium salts are cleaved 
by dehydrogenases of viable cells to produce formazan. The amount of formazan dye 
is quantified by using an ELISA plate reader at 440 nm. Cell survival was defined as: 
Cell survival = (Aexperimental - Abackground)/(Acontrol - Abackground) x 100%, with Aexperimental being 
the absorbance of drug incubated cells plus WST-1, Abackground being the absorbance of 
culture medium plus WST-1 in the absence of cells and Acontrol being the absorbance 
of cells without drugs plus WST-1. Test results were obtained from three independent 
experiments, each performed in triplicate. 
Statistics
One way ANOVA analysis was used to compare the effect of incubation-time. A 
p-value < 0.05 was considered statistically significant. Data were normalized to 
untreated cells using GraphPad Prism, to calculate the concentration at which cell 
survival is 50% (IC50). All statistical analyses and calculations were carried out using 
GraphPad Prism (version 4.0; GraphPad Software, San Diego, California, USA).
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Results
The incubation of HepG2 cells with increasing concentrations of infliximab did 
not result in significant changes in cell viability, indicating that a direct in vitro 
cytotoxic effect was absent (figure 4.1). At all concentrations of infliximab tested after 
24, 48 or 72 hours of incubation, cell survival was above 50% and no IC50 values 
could be determined (table 4.1). Only at the highest concentration of 5mg/l, could a 
decrease of about 30% in cell survival be seen (figure 4.1). Concentration-dependent 
cytotoxicity was clearly observed when HepG2 cells were incubated with increasing 
concentrations of azathioprine, 6-mercaptopurine or 6-thioguanine (figure 4.2). Only 
methotrexate showed a time-dependent cytotoxic effect on HepG2 cells. Incubation 
with various concentrations of methotrexate for 72 hours resulted in a significant 
difference in survival when compared to 24 hours of incubation (p < 0.01). 
After 24 hours incubation, neither the combination of infliximab (0.002 mg/l - 5 g/l) 
with a low dose (1 µM) of azathioprine nor the combination of a single, non-toxic 
concentration of infliximab (312 mg/l) in combination with azathioprine (0.002 µM 
- 4 mM) did show any difference in cell survival (data not shown).
Figure 4.1: Cell survival of HepG2 cells after exposure to 
various concentrations of infliximab for 24, 48 or 72 hours. 
Cell survival was expressed as a percentage of untreated cells. 
Values are means ± SEM of three independent experiments 
performed in triplicate. 
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Table 4.1 Cytotoxicity of IBD drugs in HepG2 cells.
IC50 [μM] 
Azathioprine 6-Mercaptopurine 6-Thioguanine Methotrexate Infliximab
24 hours 33.7 ± 29.3 3.8 ± 4.1 1.1 ± 0.8 NA NA
48 hours 0.5 ± 0.3 0.5 ± 0.6 0.4 ± 0.5 9.3 ± 16.0 NA
72 hours 0.9 ± 0.6 0.4 ± 0.3 0.5 ± 0.7 0.04 ± 0.03 NA
Values are mean IC50 ± SD (n = 9) derived from after normalization of dose response 
curves using Graphpad Prism. NA; not applicable (IC50 value was not reached)
Discussion
In this study infliximab showed no direct cytotoxic effect on HepG2 cells, even at 
concentrations far exceeding the maximum concentration of 118 µg/ml, which 
infliximab achieves when administered at a dosage of 5 mg/kg IV.10 Concomitant 
incubation with both infliximab in different dosages and azathioprine at a non toxic 
concentration did not alter HepG2 cell viability. Our in vitro results therefore suggest 
that a direct hepatotoxicity of infliximab is implausible. Alternatively, infliximab-
induced hepatotoxicity is more likely to be immuno-mediated or induced via Fc 
receptor-mediated interactions. After forming an immune complex with TNF-α, 
this complex is cleared by the mononuclear phagocytic system in the liver via Fc 
receptor-mediated interactions that in turn can activate Kupffer cells. These resident 
macrophages of the liver located in hepatic sinusoids, do release reactive oxygen 
species which may lead to local damage of hepatocytes.11-13 During infliximab 
therapy, increased formation of anti-nuclear antibodies has been observed,14 most 
possible due to the fact that binding of infliximab to transmembrane TNF on the cell 
surface induces apoptosis, leading to the release of nucleosomes and generation of 
anti-nuclear antibodies.15 Since antibodies to TNF-α delay the repair of liver injury,16, 
17 the use of infliximab might also exacerbate a previous suboptimal liver condition 
not recognized by any clinical symptoms or biochemical markers. Furthermore, 
a potential hepato-protective effect of TNF-α induced by increasing hepatocyte 
regeneration and decreasing apoptosis has been observed in a transgenic mouse 
model of chronic hepatitis C while treatment with anti-TNF-α blocked the anti-
apoptotic and regenerative effects induced by TNF-α.18
In contrast to our experience with infliximab, we observed a concentration dependent 
cytotoxic effect of the thiopurines in HepG2 cells, while methotrexate demonstrated 
a time- and concentration-dependent effect. The in vitro hepatotoxic effects of 
thiopurines have also been demonstrated by Petit et al., comparing the cytotoxicity 
of thiopurines in human hepatocytes and HepaRG cells, incubated for 24, 48, 72 and 
96 hours with 1, 5 or 25 μM of azathioprine, 6-mercaptopurine or 6-thioguanine. 
They reported a dose- and time-dependent cytotoxic effect of azathioprine and 
6-mercaptopurine in both human hepatocytes and HepRG cells, while 6-thioguanine 
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had no significant effect on human hepatocytes. However, 72 hours of incubation 
with either 5 or 25 μM of 6-thioguanine showed a 30% decrease in cell survival of 
HepaRG cells.19 
The observed time-dependent cytotoxic effect of methotrexate in our study is in line 
with results of Yin et al. who reported a time- and concentration dependent effect 
of high dose methotrexate (1 - 10 mM) in rat hepatocytes.20 These concentrations 
however go far beyond the mean peak concentration in human plasma of 1.14 µM 
achieved after subcutaneous administration of 15 mg methotrexate to patients with 
IBD.21
Several limitations of our study should be noticed. First of all, results of in vitro studies 
cannot be directly extrapolated to the in vivo situation. Isolated liver (carcinoma) 
cells will respond differently to stress or toxic compounds than to an intact and 
perfused liver. Therefore, although results from cell lines add to the understanding 
of drug-induced toxicity, they will be difficult to translate into clinical practice. 
Processes of absorption, distribution, metabolism and excretion, which determine 
the exposure of the target tissues of an organism in vivo, are mainly absent in in vitro 
studies.22 Furthermore, peripheral serum or plasma concentrations do not reflect 
the concentrations in the portal vein. Therefore the drug concentrations to which 
the liver is exposed are largely unknown. These points are especially true for the 
thiopurines. Resorption is highly variable in animal studies as well as in patients with 
IBD and the pro-drugs azathioprine and 6-mercaptopurine are rapidly converted.23-26 
Additionally, as in hepatocytes in the primary culture, changes in the expression 
of drug metabolizing enzymes over time occur in HepG2 cells.27 Therefore neither 
primary cultures of hepatocytes nor HepG2 cells display an ideal model mimicking 
the expression levels of drug metabolizing enzymes as present in hepatocytes in 
vivo, thereby limiting the reproducibility of in vitro hepatotoxicity experiments 
using different cell cultures.27 In our study we focused on cell viability as a marker 
of hepatotoxicity. Alterations in pathways underlying cell death including oxidative 
stress were not studied.
In conclusion, our study suggest that infliximab does not have a direct toxic effect 
on HepG2 cells. In addition, infliximab in combination with thiopurines does not 
increase their in vitro toxicity on HepG2 cells. Our results may not be translated to 
clinical practice directly without considering the limitations of these findings. On 
the other hand, no alarming cytotoxicity is seen in the same assay that shows evident 
dose-related thiopurine cytotoxicity. Future studies regarding the hepatotoxic effects 
of infliximab should focus on Fc receptor-mediated interactions and auto-immune 
related factors.
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An imbalance between the production of reactive oxygen species (ROS) and their 
capturing by antioxidants results in oxidative stress. This may play an important 
role in the pathogenesis of inflammatory bowel disease (IBD). Since bilirubin is an 
important endogenous antioxidant, increased levels of bilirubin may protect against 
IBD. UDP-glucuronosyltransferase 1A1 (UGT1A1) is the only enzyme involved in 
the conjugation of bilirubin and the common UGT1A1*28 allele in the UGT1A1 
gene, which is strongly associated with Gilbert’s syndrome in Caucasians, results in 
elevated plasma bilirubin levels.
We tested the hypothesis that the UGT1A1*28 allele is associated with lower disease 
susceptibility to, and disease behavior within, IBD. In addition, a possible altered risk 
for developing IBD-drug related side-effects was explored.
Genomic DNA of 751 patients with IBD (209 patients with ulcerative colitis and 
542 patients with Crohn’s disease) and 930 healthy controls was genotyped for the 
UGT1A1*28 promoter polymorphism, and genotype distribution was compared 
between patients and controls. Genotype phenotype interactions were also 
investigated.
Patients with Crohn’s disease significantly less often bear the UGT1A1*28 homozygous 
genotype compared to the control group, with an odds ratio of 0.64, 95% CI: 0.42 
- 0.98. The ulcerative colitis group showed no significant differences compared to 
controls.
The homozygous state of the UGT1A1*28 polymorphism, associated with higher 
serum bilirubin levels, may be protective for the development of Crohn’s disease, 
suggesting that the anti-oxidant capacity of bilirubin may play a part.
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Introduction
Over the last decades, extensive research has been performed to unravel the 
pathogenesis of inflammatory bowel disease (IBD), which encompasses both Crohn’s 
disease and ulcerative colitis. It appears that both genetic and environmental factors, 
including the enteric microbiota and food antigens as well as an altered innate 
and adaptive immune system, all may be involved.1 Oxidative stress is one of the 
pathways leading to cellular damage, which is also presumed to play an important 
role in the pathogenesis of IBD. Oxidative stress is the result of an imbalance between 
the production of reactive oxygen species (ROS), which are highly reactive due to 
the presence of unpaired electrons, and their removal by antioxidants.2 Notably of 
importance in IBD is the production of large amounts of ROS, known as respiratory 
burst, by neutrophils and macrophages after activation by pro-inflammatory agents 
like cytokines, immune complexes or bacterial products.3 In neutrophils derived 
from the intestinal mucosa of patients with IBD, an increased production of ROS 
has been observed.4 Furthermore in patients with IBD, intestinal subepithelial 
myofibroblasts exhibited an increased oxidative state related to elevated levels of 
interleukin-6.5 Oxidative stress might therefore be responsible for the increased 
synthesis of cytokines which accentuate and amplify the inflammatory state in 
patients with Crohn’s disease.5 A recent study characterized the ROS generated in 
immune peripheral cells in patients with Crohn’s disease, and showed a significant 
increase in H2O2 in both active and remission phases of the disease, while anti-
oxidative mechanisms catalyzing the decomposition of H2O2 were impaired.6
Intestinal damage in IBD has been suggested to be caused by an increased production 
of ROS and an impaired antioxidant capacity.2, 7, 8 Bilirubin, which is formed during the 
catabolism of heme, has for a long time been regarded only as a toxic waste product, 
causing jaundice or kernicterus when not properly cleared. However, bilirubin 
has since proved to be a powerful endogenous chain-breaking antioxidant, and a 
protective role of bilirubin has been suggested in coronary artery disease, respiratory 
diseases and cancer.9-14 A chronic mild form of unconjugated hyperbilirubinemia in 
the absence of liver disease or overt hemolysis is known as Gilbert’s syndrome. In 
Caucasians, it is mainly caused by homozygosity for a polymorphism in the promoter 
region of the UTG1A1 gene, known as the UGT1A1*28 allele.15, 16 Functional analyses 
of the transcriptional promoter activity demonstrated that the UGT1A1*28 allele 
reduces the transcription of the UGT1A1 gene up to 20% of normal.17 UGT1A1 
is the only enzyme that catalyzes glucuronidation of bilirubin, which is the main 
determinant of elimination of bilirubin in humans.18 Genotypes including the 
UGT1A1*28 allele are associated with a reduced hepatic UGT1A1 enzyme activity 
up to 50%, with subsequent increased blood levels of unconjugated bilirubin, as 
compared with the most common UGT1A1*1 genotypes.15, 19, 20 Recent genome-wide 
association studies (GWAS) have also confirmed the substantial genetic influence of 
UGT1A1 variants on bilirubin levels.21, 22
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In 2006, Seiderer and co-workers reported on a patient suffering from both Crohn’s 
disease and Gilbert’s syndrome, who developed nodular regenerative hyperplasia 
following treatment with azathioprine, suggesting a predisposition of the UGT1A1*28 
allele for abnormal thiopurine interactions.23 In fact, the UGT1A1*28 allele is 
strongly associated with irinotecan toxicity, a drug often used in the treatment of 
metastatic colorectal cancer.24 We hypothesized that individuals bearing this allele, 
which is associated with reduced bilirubin conjugating enzyme activity and therefore 
increased bilirubin levels, are at a reduced risk for developing IBD. Since thiopurines 
(i.e. azathiopurine, 6-mercaptopurine and 6-thioguanine) are effective and widely 
used drugs in patients with IBD,25, we also aimed to explore the risk of thiopurine-
induced side effects in patients bearing this polymorphism in a nested case approach.
Materials and methods
Patients
Patients with a diagnosis of IBD based on accepted clinical, endoscopic, radiological 
and histological findings,26 were recruited at the outpatient clinic of the Department 
of Gastroenterology, Radboud University Nijmegen Medical Center, being a tertiary 
referral center for IBD. A total number of 751 Caucasian patients (39% men, median 
age at diagnosis 26 years, range 4-76 years) were included, 542 patients with Crohn’s 
disease (36% men, median age at diagnosis 24 years, range 4-76 years) and 209 
patients with ulcerative colitis (48% men, median age at diagnosis 30 years, range 
11-72 years). Furthermore, a total number of 930 healthy controls (43% men, median 
age 43 years, range 18-90 years), recruited from the referral region of our hospital, 
were included in the study. Blood samples were collected over a period of more than 
10 years (1998-2010), while genotyping of all samples was performed in June 2010. 
Clinical characteristics of the patients, including disease extent according to the 
Montreal classification,27 family history of IBD, necessity of surgery and occurrence of 
extra-intestinal manifestations, were obtained at last follow-up in 2010, as described 
before.28 Basic characteristics of both cases and controls are given in supplementary 
table 5.1. Apart from clinical characteristics, we also collected data on thiopurine 
use and necessity to stop medication due to side effects. Side effects were categorized 
into gastro-intestinal intolerance (diarrhea, nausea and vomiting, abdominal pain), 
allergy (fever, skin rash, arthralgia/myalgia, Stevens Johnsons Syndrome), infection 
(Herpes zoster, fever of unknown origin, pneumonia), myelotoxicity (leukopenia 
and/or thrombocytopenia), hepatotoxicity (abnormal liver function tests) or 
pancreatic toxicity (abnormal pancreas enzymes, pancreatitis) and miscellaneous 
(fatigue, dizziness, generally unwell), based on laboratory results if appropriate. The 
mean follow-up of the patient cohort with Crohn’s disease was 17.4 years (standard 
deviation (SD) 10.6), while the mean follow-up in the ulcerative colitis cohort was 
15.1 years (SD 8.8). 
Prior to study recruitment, 2 patients had been diagnosed with Gilbert’s syndrome, 1 
patient with ulcerative colitis and 1 patient with Crohn’s disease.
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Genotyping
DNA of both patients and controls was isolated from whole blood by use of the 
Pure Gene DNA isolation kit (Gentra Systems, Minneapolis, MN).28 We determined 
the number of TA repeats in the promoter region of the UGT1A1 gene by using 
the polymerase chain reaction (PCR) conditions and primers as described before 
by Monaghan et al.16 Amplification was confirmed by agarose electrophoresis 
before fragments were resolved on 12% polyacrylamide gels (19:1 acrylamide/
bisacrylamide; Biorad Laboratories, Veenendaal, The Netherlands) in Tris-borate-
EDTA buffer. Electrophoresis was run at 400 V for 4 h and gels were stained with 
ethidium bromide for 15 min.19 Fragments of 98 bp indicate the UGT1A1*1 allele 
containing 6 TA repeats and fragments of 100 bp indicate the UGT1A1*28 allele, 
containing 7 TA repeats.29
Statistical analysis
The observed genotype frequencies were tested for deviation from the Hardy-
Weinberg equilibrium using Fisher’s exact test. Differences in UGT1A1 genotype 
distributions between patients and controls were determined by using the χ2 test, 
and odds ratios (ORs) with 95% confidence interval (95% CI) were calculated for 
genotypes associated with predicted normal, versus predicted altered UGT1A1 
enzyme activities (variant genotypes). In addition, we calculated the generalized 
odds ratio (ORG), which utilizes the complete genotype distribution. It can be defined 
as the probability of a subject being more diseased relative to the probability of being 
less diseased, given that the more diseased subject has a higher mutational load.30 The 
ORG and 95% CI were calculated using the software “ORGGASMA” (downloaded 
from http://biomath.med.uth.gr). Lastly, we investigated whether an altered predicted 
enzyme activity influenced disease location or behavior, as well as for thiopurine side 
effects. Differences were calculated by using the χ2 test or Fisher’s exact test when 
appropriate. Statistical analysis was performed using GraphPad Prism version 4.00 
(GraphPad Software, San Diego, CA).
Ethics
The ethical committee of region Nijmegen and Arnhem reviewed and approved the 
protocol under number CWOM-nr 9804-0100. Verbal informed consent was obtained 
from each patient before study participation in agreement with the approval and all 
samples were anonymized. Since research data were collected anonymously, at least 
verbal informed consent was needed according to national regulations. Therefore, no 
written informed consent procedure was introduced at time of data collection.
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Results
Distribution of the UGT1A1 genotypes
Distribution of the UGT1A1 genotypes in the control and patient groups, did fit 
the Hardy Weinberg equilibrium (p = 0.40 and p = 0.13, respectively). In patients 
with Crohn’s disease, comparing the homozygous UGT1A1*28 and the homozygous 
UGT1A1*1 genotype, correlating with low and high bilirubin UGT enzyme activity 
respectively, revealed a significant difference (OR = 0.64, 95% CI 0.42-0.98; p = 
0.04, table 5.1). For patients with ulcerative colitis however, such difference was 
not observed. No differences were seen when Crohn’s disease patients with the 
heterogenous genotype, corresponding with predicted intermediate enzyme activity, 
were compared to the homozygous UGT1A1*1 genotypes (table 5.1). Furthermore, 
there was a decreased incidence of extra-intestinal manifestations in UGT1A1*28 
allele barriers compared to wildtype carriers in patients with Crohn’s disease (OR  = 
0.60, 95% CI 0.40-0.89; p = 0.009, table 5.2), which however lost significance after 
Bonferroni correction. The UGT1A1*28 allele had no effect on disease location 
or the need of disease related surgery in patients with ulcerative colitis (table 5.3). 
The generalized odds ratio (ORG), which provides an estimate of the magnitude of 
the association between disease status and genotype, was calculated by comparing 
patients with Crohn’s disease and controls and showed a non significant association 
(ORG = 0.83, 95% CI 0.69-1.01).
Possible relationship between UGT1A1 genotype and thiopurine-induced side effects
We subsequently explored the possible relationship between the UGT1A1*28 allele 
and thiopurine induced side effects. Data on thiopurine use were available for 585 
patients, 407 patients with Crohn’s disease and 178 patients with ulcerative colitis. 
Of these patients, 343 patients used azathioprine, 53 patients used azathioprine 
in combination with 6-mercaptopurine (6-MP), 17 patients used azathioprine 
in combination with 6-thioguanine (6-TG), and 9 patients used azathioprine in 
combination with both 6-MP and 6-TG. A total of 126 thiopurine side effects were 
observed, 95 in patients with Crohn’s disease and 31 in patients with ulcerative colitis. 
However, no significant association was observed between thiopurine related side 
effects and the presence of the UGT1A1*28 allele (OR = 1.17, 95% CI 0.77-1.79; p 
= 0.46). However, when subgroups were analyzed, gastrointestinal intolerance to 
thiopurine therapy was associated with the UGT1A1*28 allele (OR 2.26, 95% CI 1.11-
4.62; p = 0.02, table 5.4). After Bonferroni correction however, this p-value did not 
remain significant.
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Table 5.2 UGT1A1 genotype-phenotype correlations in patients with Crohn’s disease#
*1/*1
(n = 268)
*1/*28
(n = 223)
*28/*28
(n = 27)
Odds ratio 
(95% CI)
p-
value
Disease location†
Ileal 89 83 9 Reference
Colonic 71 46 3 0.67 (0.42-1.06) 0.09
Ileocolonic 102 88 15 0.98 (0.65-1.46) 0.91
Isolated upper disease+ 15 15 4 1.23 (0.59-2.56) 0.59
Disease behaviour†
Non stricturing/ penetrating 85 69 9 Reference
Stricturing 45 42 0 1.02 (0.60-1.71) 0.95
Penetrating 132 106 18 1.02 (0.69-1.52) 0.91
Age at diagnosis†
< 16 years 24 28 1 Reference
Between 17 and 40 years 208 171 23 0.77 (0.43-1.37) 0.38
Above 40 years 36 21 7 0.64 (0.31-1.34) 0.24
Surgery 164 132 19 0.97 (0.68-1.38) 0.85
Extra-intestinal 92/246 54/201 6/26 0.60 (0.40-0.89) 0.01
Family history of IBD 38/132 31/108 4/20 0.93 (0.54-1.60) 0.80
#The UGT1A1*1/*1 genotypes were compared with the patients bearing the UGT1A1*28 
allele (both homo- and heterozygous). Note that phenotypes of not all patients were 
available. Significant p-values are given in bold letters including corresponding odds 
ratios (OR) and 95% confidence intervals (CI). However, none of these P-values remained 
significant after Bonferroni correction (p > 0.05).
+Patients were classified as having disease localization in the upper gastrointestinal tract 
next to ileal, ileo-colonic or colonic localization
†According to the Montreal Classification
Table 5.3 UGT1A1 genotype-phenotype correlations in patients with ulcerative colitis#
*1/*1 *1/*28 *28/*28 Odds ratio
(95% CI)
p-
value
Disease localization (n = 176)†
Proctitis 5 4 2 Reference
Left sided 25 29 6 1.17 (0.32-4.25) 0.82
Pancolitis 57 39 9 0.70 (0.20-2.44) 0.58
Surgery (n = 194) 30/96 23/80 4/18 0.84 (0.45-1.55) 0.58
#The UGT1A1*1/*1 genotypes were compared with the patients bearing the UGT1A1*28 
variant (both homozygous and heterozygous). Note that phenotypes of not all patients were 
available 
†According to the Montreal Classification.
Chapter 5 80
Table 5.4 Thiopurine side effects stratified by UGT1A1 genotype#
*1/*1
(n = 208)
*1/*28
(n = 184)
*28/*28
(n = 32)
Odds ratio
(95% CI)
p-value
No adverse event 143 126 18 Reference
Total adverse events 65 58 14 1.10 (0.73-1.65) 0.65
Gastrointestinal intolerance 12 24 2 2.15 (1.05-4.43) 0.03
Allergy 24 17 5 0.91 (0.49-1.70) 0.77
Infection 3 0 1 0.33 (0.03-3.22) 0.62
Myelotoxicity 9 6 1 0.77 (0.28-2.13) 0.62
Hepatotoxicity 8 4 3 0.87 (0.31-2.46) 0.79
Pancreas toxicity 5 6 0 1.19 (0.36-3.99) 1.00
Miscellaneous 4 1 2 0.74 (0.16-3.39) 1.00
#The UGT1A1*1/*1 genotypes were compared with the patients bearing the UGT1A1*28 
allele (both homo- and heterozygous).
Discussion
In our cohort, homozygosity for the UGT1A1*28 allele, which correlates with 
low enzyme activity, exerted a protective effect against Crohn’s disease. The 9.0% 
prevalence of homozygosity for the UGT1A1*28 allele in our control population is 
lower compared to homozygosity rates of 12% reported in other European studies,16, 
31 which might even more emphasize the significance of our finding. A detailed 
genotype-phenotype analysis revealed a weak association of the UGT1A1*28 allele 
with a decreased incidence of extra-intestinal manifestations, which however did not 
remain significant after Bonferroni correction. The results of our study could imply 
that an increased blood level of unconjugated bilirubin confers a protective effect on 
the development of Crohn’s disease. In accordance with this hypothesis, Koutroubakis 
and co-workers showed that patients with inflammatory bowel disease had a decreased 
serum antioxidant capacity as compared to healthy controls, with bilirubin acting as 
one of the major endogenous anti-oxidants accounting for this antioxidant capacity.32 
Furthermore, several animal studies have indicated a protective role of the products 
formed during heme catabolism, including heme oxygenase (HO), carbon monoxide 
(CO) and biliverdin-bilirubin, in the pathogenesis of inflammatory bowel disease.33-35 
Decreased levels of bilirubin have also been associated with other auto-inflammatory 
diseases in which oxidative stress also seems to be pathogenically involved, including 
rheumatoid arthritis and systemic lupus erythematosus.36-39 
In the catabolism of heme, the stress responsive enzyme HO-1 is involved, which 
together with HO-2, are the rate limiting enzymes in the formation of biliverdin, 
which successively is converted into bilirubin, free iron and CO.40 In an experimental 
colitis model administering dextran sodium sulfate (DSS) to rats, Berberat et al. 
showed that induction of intestinal HO-1 ameliorates manifestations of DSS induced 
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induced colitis. Daily intraperitoneal injections of biliverdin resulted in a comparable 
protective effect, indicating that the generation of bilirubin by the up-regulation 
of HO-1 may be the key mediator in suppressing inflammatory damage in acute 
colitis.41 In rats treated with trinitrobenzene sulphonic acid (TNBS) to induce colitis, 
increased expression and activity of HO-1, as measured by formation of bilirubin, 
was observed after TNBS challenge.42 
In this study we explored the possible link between Gilbert’s syndrome and the 
development of thiopurine-induced side effects, by investigation the association of 
the UGT1A1*28 allele and thiopurine related side effects.23 No association was found; 
while a sub analysis revealed that bearing the UGT1A1*28 allele was associated with 
gastrointestinal intolerance for thiopurines. This association however, did not remain 
significant after correction for multiple comparisons. Furthermore, this finding might 
also be explained as a by chance finding due to the small groups analyzed. Thiopurine 
prodrugs are converted intracellularly into cytotoxic 6-thioguanine nucleotides (6-
TGNs) to exert their therapeutic effect, but UGTs seem to be not involved in the 
metabolism of the prodrugs. Therefore it is unclear how UGT1A1 might be involved in 
the occurrence of gastrointestinal intolerance. An enzyme which certainly is involved 
in the catabolism of thiopurines, the thiopurine S methyltransferase (TPMT), is a 
major determinant for 6-TGNs levels.43 High levels of 6-TGNs are associated with 
thiopurine side effects and different variants of TPMT exist which may result in 
altered TPMT activity. A recent meta-analysis showed an association between TPMT 
polymorphisms and thiopurine side effects in patients with IBD.44 However, not all 
side effects of thiopurine therapy could be explained by TPMT polymorphisms, 
which implies that other mechanisms, unrelated to TPMT, might play a role.45 A 
limitation of our study might be that we did not measure blood, serum or plasma 
levels of bilirubin in our patients, but only used the UGT1A1*28 allele as an indirect 
parameter for hyperbilirubinemia. However, multiple studies have confirmed the 
relationship between the UGT1A1*28 polymorphism and elevated plasma/serum/
blood levels of bilirubin.16, 18, 46 
Conclusion
Homozygosity for the UGT1A1*28 allele exerted a protective effect against the 
development of Crohn’s disease, as well on the development of extra-intestinal 
manifestations of Crohn’s disease in a Dutch cohort of IBD patients. Most likely this 
protective effect is due to the antioxidant capacity of the slightly elevated bilirubin 
levels. If firmly established, this might possibly lead to new strategies in the prevention 
or support treatment of Crohn’s disease by supplementation with antioxidants.
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Supplementary table  5.1 Basic characteristics of patients and controls
Controls 
(n=930)
Crohn’s disease
(n=542)
Ulcerative colitis
(n=209)
Median age, years 
(range)
43 (18-90) 44 (17-84) 45 (19-82)
Sex
Male 396 43% 200 37% 97 46%
Female 534 57% 342 63% 112 54%
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Dectin-1 is a pattern recognition receptor (PRR) expressed by myeloid cells that 
specifically recognizes β-1,3 glucan, a polysaccharide and major component of the 
fungal cell wall. Upon activation, dectin-1 signaling converges, similar to NOD2, on 
the adaptor molecule CARD9 which is associated with inflammatory bowel disease 
(IBD). An early stop codon polymorphism (c.714T>G) in DECTIN-1 results in a 
loss-of-function (p.Y238X) and impaired cytokine responses, including TNF-α, 
interleukin (IL)-1β and IL-17 upon in vitro stimulation with Candida albicans or 
β-glucan. The aim of the present study was to test the hypothesis that the DECTIN-1 
c.714T>G (p.Y238X) polymorphism is associated with lower disease susceptibility 
or severity in IBD and to investigate the level of dectin-1 expression in inflamed and 
non-inflamed colon tissue of IBD patients. 
Paraffin embedded tissue samples from non-inflamed and inflamed colon of IBD 
patients and from diverticulitis patients were immunohistochemically stained for 
dectin-1 and related to CD68 macrophage staining. Genomic DNA of IBD patients 
(778 patients with Crohn’s disease and 759 patients with ulcerative colitis) and healthy 
controls (n = 772) was genotyped for the c.714T>G polymorphism and genotype-
phenotype interactions were investigated.
Increased expression of dectin-1 was observed in actively inflamed colon tissue, as 
compared to non-inflamed tissue of the same patients. Also an increase in dectin-1 
expression was apparent in diverticulitis tissue. No statistically significant difference 
in DECTIN-1 c.714T>G allele frequencies was observed between IBD patients 
and healthy controls. Furthermore, no differences in clinical characteristics could 
be observed related to DECTIN-1 genotype, neither alone, nor stratified for NOD2 
genotype.
Our data demonstrate that dectin-1 expression is elevated on macrophages, 
neutrophils, and other immune cells involved in the inflammatory reaction in IBD. 
The DECTIN-1 c.714T>G polymorphism however, is not a major susceptibility factor 
for developing IBD.
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Introduction
Inflammatory bowel disease (IBD), is an idiopathic, chronic, relapsing inflammatory 
disorder of the gastrointestinal tract. It is commonly accepted that IBD is caused 
by an exaggerated cell mediated immune response to intestinal microbiota in 
genetically susceptible individuals.1, 2 IBD mainly involves two distinct diseases, 
which show some overlap: Crohn’s disease (CD) and ulcerative colitis (UC). Genetic 
susceptibility is more pronounced in CD compared to UC.3 Several susceptibility loci 
for developing CD have been identified in the past decades including the NOD2 gene 
within the IBD1 locus.4 The established association of NOD2 (CARD15) with CD 
emphasizes the important role of the intestinal microbiota in the pathogenesis of CD, 
since NOD2 acts as an intracellular pattern recognition receptor (PRR) recognizing 
bacterial peptidoglycans.5, 6
Dectin-1 (CLEC7A) is a pattern-recognition receptor expressed by myeloid cells 
which specifically recognizes β-(1,3)-glucan, a polysaccharide and component of 
the fungal cell wall. As a result, dectin-1 is involved in recognition of fungi such as 
Candida albicans and Aspergillus fumigatus. Upon activation, dectin-1 recruits spleen 
tyrosine kinase (Syk) which in turn activates NF-κB, requiring the adaptor molecule 
Caspase Activating Recruitment Domain 9 (CARD9), a key adaptor for non-Toll 
Like Receptor (TLR) signal transduction.7 Although not the exclusive pathway, 
CARD9 also has a critical function in NOD2-mediated activation of the kinases 
p38 and Jnk, required for the production of pro-inflammatory cytokines in innate 
immune responses to intracellular pathogens.8 LeibundGut-Landmann et al. showed 
that dectin-1-Syk-CARD9 signaling induces dendritic cell (DC) maturation and 
secretion of pro-inflammatory cytokines like interleukin (IL)-6, TNF-α, IL-17 and 
IL-23.9 Furthermore, Zhernakova et al. identified CARD9 as a susceptibility locus for 
IBD.10 Recently, the DECTIN-1 polymorphism c.714T>G on chromosome 12p13 has 
been described, with a transition from a tyrosine to an early stop codon on amino 
acid position 238 (p.Y238X).11 The functional consequence of this polymorphism 
is a complete loss-of-function, and immune cells expressing this truncated protein 
produce significantly less cytokines, including TNF-α, IL-1β and IL-17, upon in vitro 
stimulation with β-glucan or Candida albicans.12
Th17 responses are considered to be involved in the pathogenesis of auto-immune 
diseases. This T cell subset appears to play a role in the etiology of CD since IL-
17 is up-regulated in the intestine of IBD patients.13 Interestingly, both NOD2 and 
dectin-1 are shown to be capable of inducing Th17 responses after activation.9, 14 
In this respect, the DECTIN-1 c.714T>G polymorphism could influence the Th17 
response towards fungi such as Candida albicans, a commensal microorganism of the 
gastrointestinal tract. Candida albicans is also one of the immunogens for developing 
antibodies against Saccharomyces cerevisiae (ASCA), which are regularly observed in 
patients with CD.15, 16
Taking together the data from various studies, a dysregulation of the immune 
response to the commensal Candida albicans through dectin-1 and IL-17 release 
might play a role in the pathogenesis of CD.
DECTIN-1 c.714t>g polymorphism in ibd | 89
As stated above, activation of NOD2 and dectin-1 leads to signaling through a shared 
pathway (CARD9). The importance of this pathway in CD is demonstrated by the 
fact that mutations in NOD2 and CARD9 and the presence of circulating ASCA, are 
associated with CD. Since the c.714T>G polymorphism within DECTIN-1 results 
in a loss of function, we hypothesized that this polymorphism could be potentially 
protective against developing IBD. Therefore, we aimed to elucidate the role of the 
DECTIN-1 c.714T>G (p.Tyr238X) polymorphism in patients with IBD, focusing on 
the occurrence and the clinical severity of IBD.
Methods
Patients
Patients with a diagnosis of IBD were recruited from the outpatient clinics of three 
university hospitals in the Netherlands: Radboud University Nijmegen Medical 
Centre (CD: n = 161, UC: n = 212), VU University Medical Centre Amsterdam (CD: 
n = 177, UC: n = 148) and the University Medical Centre Groningen (CD: n = 308, 
UC: n = 214), and one regional hospital: St. Anna Hospital, Geldrop (CD: n = 132, 
UC: n = 185). Healthy controls were recruited at the Radboud University Nijmegen 
Medical Centre and at the University Medical Centre Groningen (n = 772).
Diagnosis of IBD was based on accepted clinical, endoscopic, radiological and 
histological findings.17 Clinical data on patients were retrieved by retrospective 
collection from patients’ clinical charts. Clinical data on patients from the VU 
University Medical Centre were collected prospectively. The following data were 
obtained from patients with CD: age, age at diagnosis, gender, familial or sporadic IBD, 
disease localization and behavior of disease (according to the Vienna classification18), 
extra-intestinal manifestations, peri-anal disease, and surgery for CD. For patients 
with UC, the following data were obtained: age, age at diagnosis, disease location 
(according to the Montreal classification19), familial or sporadic IBD, extra intestinal 
manifestations, surgery for UC, and occurrence of colorectal cancer.
The ethical committee of region Nijmegen and Arnhem reviewed and approved 
the protocol under number CWOM-nr 9804-0100. Verbal informed consent 
was obtained from each patient before study participation in agreement with the 
approval and all samples were anonymized. Given the fact that all research data were 
anonymously collected, at least verbal informed consent was needed according to 
national regulations. Therefore, since written informed consent was not required, no 
written informed consent procedure was introduced at time of data collection.
Genotyping of c.714T>G polymorphism in DECTIN-1
Genomic DNA was isolated from peripheral venous blood using standard techniques 
and stored at 4°C. Genotyping of the c.714T>G (p.Y238X) polymorphism in exon 
6 of the DECTIN-1 gene in the patient and healthy control groups from Nijmegen, 
Amsterdam and Geldrop was performed by applying the predesigned TaqMan SNP 
assay C_33748481_10 (rs 16910526) on the 7300 ABI Real-Time PCR system (both 
from Applied Biosystems, Foster City, CA, USA) using 96-well plates. 
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Genotyping of the IBD cohort and healthy controls from Groningen, was performed 
at the Department of Genetics, UMC Groningen, the Netherlands, applying the 
same predesigned TaqMan SNP assay, using the 7900 ABI Real-Time PCR system 
(Applied Biosystems, Foster City, CA, USA). The patient and control DNA samples 
from Groningen were processed in 384-well plates and each plate also contained 16 
genotyping controls (4 duplicates of the Centre d’Etudes du Polymorphisme Humain 
(CEPH) DNA samples 123002,102405,090203 and 081505). For all polymorphisms 
we obtained >99.8% concordance between our CEPH genotype data and the CEU 
(European ancestry) data available from HapMap.
Genotyping of NOD2 variants
Data on the three common NOD2 variants were available for CD patients 
from Groningen and Nijmegen (p.Arg702Trp; n =437, p.Gly908Arg; n= 446, 
p.Leu1007ProfsX2; n= 436). Genotyping of these three NOD2 variants (c.2104C.T 
(p.Arg702Trp), c.2722G.C (p.Gly908Arg), c.3019_3020insC (p.Leu1007ProfsX2)) 
has been described before.20
Immunohistochemical staining
Dectin-1 and CD68 protein expression were evaluated by immunohistochemical 
staining in paraffin embedded normal and inflamed colon tissue of five IBD patients 
and 4 patients with diverticulitis, all homozygous for the DECTIN-1 wild-type 
allele (T/T). The applied primary antibodies were a monoclonal mouse-anti-human 
dectin-1 antibody (MAB 1859, purchased from R&D Biosystems, Minneapolis, MN, 
USA), used in a concentration of 5 µg/ml and a monoclonal mouse-anti-human 
antibody against CD68 (MCA1815T, purchased from AbD Serotec, Oxford, UK) 
which was diluted 100 times before use. After overnight incubation with the primary 
antibody, the tissue sections were incubated for 1 hour with a secondary antibody 
after washing with PBS. Subsequently the staining was visualized by applying ABC 
complex and DAB solution. Sections were counterstained with haematoxylin.
Statistics
Statistical analysis was performed by using SPSS statistical software, version 16.0 
(SPSS Inc., Chicago, IL). Controls and IBD patients were tested for Hardy Weinberg 
equilibrium. Allele frequencies were compared between patients and controls using 
the χ2 test. P-values were obtained by comparing individuals carrying at least one 
DECTIN-1 G allele (G/G genotype and T/G genotype) with wild-type individuals 
(T/T genotype). Continuous variables were compared using Student t-tests. Strength 
of association between genotype and phenotype is given as odds ratio with 95% 
confidence interval (CI). Statistical interaction between NOD2 variants and the 
c.714T>G polymorphism regarding clinical characteristics, was investigated by 
comparing patients carrying a NOD2 susceptibility allele in combination with 
carrying one or two copies of the DECTIN-1 G allele, to patients not bearing any of 
these NOD2 or DECTIN-1 minor alleles. 
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This combined analysis for c.714T>G and NOD2 was performed for each of the three 
NOD2 susceptibility alleles. A P-value <0.05 was considered significant.
Results
Protein expression of dectin-1 in intestinal tissue
Dectin-1 and CD68 staining was performed on matched intestinal tissue samples 
from five IBD patients, either inflamed or non-inflamed, as depicted in figure 6.1 and 
6.2. Dectin-1 expression is mainly present on macrophages as showed by staining 
for CD68 (figure 6.1). Furthermore, dectin-1 also appears to be weakly expressed on 
neutrophils, the membrane of endothelial and epithelial cells and in the submucosal 
neuronal plexus of Meissner (not shown). Dectin-1 appeared to be up-regulated 
within inflamed colon tissue due to increased expression of dectin-1 on inflammatory 
cells and increased influx of inflammatory cells (figure 6.1). 
Figure 6.1 Representative immunohistochemical staining of DECTIN-1 and CD-68 in 
inflamed and non-inflamed intestine of the same specimen in Crohn’s disease (250× 
magnified).
Macrophages are present in non-inflamed intestinal tissue but are present in increased 
numbers in inflamed tissue (pictures A and C). The expression of DECTIN-1 is increased 
in inflamed intestinal tissue compared to non-inflamed intestinal tissue (pictures B and 
D).
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In order to test whether this increased expression of dectin-1 is IBD specific, additional 
staining was performed on matched intestinal tissue samples from 4 patients with 
diverticulitis. As shown in figure 6.2, increased expression of dectin-1 was also 
observed in patients with severe diverticulitis compared to mild diverticulitis. As is 
true for patients with IBD, expression of dectin-1 is mainly present on macrophages 
as shown by CD68 staining.
Figure 6.2 Representative immunohistochemical staining of dectin-1 and CD68 in 
mild and severe diverticulitis (250× magnified).
Macrophages are present in intestinal tissue of mild diverticulitis but are present in 
increased numbers in severe diverticulitis (pictures A and B). Also, the expression of 
dectin-1 is increased in severe diverticulitis compared to mild diverticulitis (pictures 
C and D).
Distribution of the DECTIN-1 c.714T>G polymorphism in IBD patients and healthy 
controls
Characteristics of the study population and healthy controls are depicted in table 
6.1. Genotype frequencies of healthy controls were in Hardy Weinberg equilibrium. 
Carriage of at least one copy of the G allele of the DECTIN-1 polymorphism was 14% 
in the CD, 14% in the UC and 17% in the healthy control group. The frequency of 
the G allele was 9.8% in the healthy controls, 8.1% in CD patients and 7.7% in UC 
patients. Overall, no significant differences were observed between patients with IBD 
and healthy controls regarding allele frequencies of the DECTIN-1 polymorphism.
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Table 6.1 Distribution of genotypes of wild-type, heterozygous and homozygous individuals 
for the c.714T>G polymorphism 
DECTIN-1 
status
Controls % Crohn’s 
disease
% p-value Ulcerative 
colitis
% p-value
Total cohort, 
number
772 100 778 100 759 100
T/T 642 83.2 667 85.7 0.16 655 86.3 0.09
T/G 122 15.8 106 13.6 100 13.2
G/G 8 1.0 5 0.6 4 0.5
Correlation of the DECTIN-1 c.714T>G polymorphism with clinical characteristics of 
IBD patients
Patients with CD carrying one or two copies of the DECTIN-1 G allele were compared 
to patients with the wild-type genotype T/T with regard to age at diagnosis, gender, 
family history of IBD, localization of disease and disease behavior, extra intestinal 
and peri-anal disease and surgery related to CD (table 6.2). Patients with UC were 
likewise compared according to the DECTIN-1 genotypes regarding age at diagnosis, 
gender, localization of disease, extra-intestinal disease, development of malignancies, 
surgery related to UC and a positive family history for IBD (table 6.3). No statistical 
significant associations were observed between the c.714T>G polymorphism and 
specific phenotypes.
The DECTIN-1 c.714T>G polymorphism stratified by NOD2 status and clinical 
characteristics of IBD patients
CD patients carrying one or two copies of the G allele of the DECTIN-1 gene were 
stratified by NOD2 status. A NOD2 risk genotype was defined as carrying at least one 
of the three common NOD2 disease susceptibility alleles (c.2104C>T (p.Arg702Trp), 
c.2722G>C (p.Gly908Arg), c.3019_3020insC (p.Leu1007fsX1008)). Combinations of 
NOD2 risk carriers and DECTIN-1 c.714T>G carriers were compared to patients 
not bearing any of these NOD2 or DECTIN-1 minor alleles, regarding clinical 
characteristics. No statistical significant interaction between DECTIN-1 c.714T>G 
and one of the NOD2 variants was observed (data not shown).
Discussion
Signaling through dectin-1, known for its recognition of the fungal component 
β-glucan, has been described to be involved in several immunological pathways. 
Dectin-1 amplifies pro-inflammatory cytokine production induced by TLR2 and 
TLR4, and primes Th1, Th17 and cytotoxic T cell responses induced by dendritic 
cells.9, 21 The DECTIN-1 c.714T>G polymorphism results in a loss-of-function of 
dectin-1, and we hypothesized that this polymorphism could be potentially protective 
in either the susceptibility to or the disease severity of IBD.
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As shown by immunohistochemical staining of intestinal tissue, dectin-1 is mainly 
present on macrophages, but also weakly on epithelial and endothelial layers of the 
intestine. Similar findings in mice have been demonstrated by Wong and co-workers, 
who demonstrated that dectin-1 is mainly expressed on populations of myeloid cells 
(monocyte/macrophage and neutrophil lineages).22 In addition, they demonstrated 
that dectin-1 is also expressed in the Peyer’s patches and along the lamina propria of 
the mouse intestine.22,23 Interestingly, dectin-1 expression appeared to be elevated in 
inflamed intestinal tissue compared to normal tissue, due to the increased infiltration 
of immune cells and increased dectin-1 expression on the cell membrane of immune 
cells.
However, intestinal expression of dectin-1 did not appear to be disease specific 
but rather dependent on influx of macrophages. In fact, expression of dectin-1 
was also present in intestinal samples from patients with diverticulitis. Increased 
infiltration of macrophages in severe diverticulitis showed an increased expression 
of dectin-1, compared to mild diverticulitis which is accompanied by less infiltration 
of macrophages.
Cohorts of CD (n = 778) and UC (n = 759) patients were screened for the DECTIN-1 
c.714T>G polymorphism and compared to a group of healthy subjects (n = 772). 
Subsequently, these genetic data were correlated with clinical parameters reflecting 
disease severity. This analysis revealed no statistical significant association between the 
prevalence of the DECTIN-1 c.714G allele and IBD, neither in disease occurrence nor 
in disease severity. However, one can observe that homozygous individuals bearing 
the DECTIN-1 polymorphism were twice as frequent in healthy controls compared 
to IBD patients. This may suggest that complete absence of dectin-1 function could 
protect against IBD. It is important to realize that the only two dectin-1 isoforms 
capable of binding β-glucans (isoforms A and B) are structurally equally affected 
by the DECTIN-1 c.714T>G polymorphism.24 The occurrence of splicing isoforms 
with residual function could therefore be excluded. The potential mechanism of 
protection are likely to include the lower production of pro-inflammatory cytokines, 
including IL-17, in the individuals with defective dectin-1. In these series, statistical 
power to preclude any functional difference is insufficient due to the low prevalence 
of homozygous individuals. Additional studies in homozygous and heterozygous 
subpopulations are needed to confirm the reported observations.
All together, the reports of the association of mutations within NOD2 and CARD9 
in patients with CD, the presence of ASCA, and the shared signaling pathway of 
dectin-1 and NOD2, points toward a possible link between NOD2 and dectin-1.25 
Since mutations in NOD2 in CD patients are associated with ileal involvement and 
increased need for surgery and stricturing disease,26 a potential interaction between 
NOD2 mutations and the DECTIN-1 c.714T>G polymorphism with regard to 
phenotypical characteristics was investigated. However, no statistical interaction 
could be demonstrated (data not shown).
Our data demonstrate that dectin-1 expression is elevated on macrophages, 
neutrophils, and other immune cells involved in the inflammatory reaction in 
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IBD. The DECTIN-1 c.714T>G polymorphism is not a major susceptibility factor 
for protection against IBD, although a trend towards a lower frequency of the 
polymorphism in CD and UC cohorts was observed, in particular in the number of 
individuals homozygous for the DECTIN-1 polymorphism. These genetic findings 
warrant further investigation of this pathogenetic pathway.
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Cyclooxygenase-2 (COX-2) is a key enzyme involved in the conversion of arachidonic 
acid into prostaglandins. COX-2 is mainly induced at sites of inflammation in 
response to proinflammatory cytokines such as interleukin-1α/β, interferon-γ and 
tumor necrosis factor-α produced by inflammatory cells. 
The aim of this study was to investigate the possible modulating effect of the functional 
COX-2 polymorphisms -1195A→G and -765G→C on the risk for development of 
inflammatory bowel disease (IBD) in a Dutch population.
Genomic DNA of 525 patients with Crohn’s disease (CD), 211 patients with ulcerative 
colitis (UC) and 973 healthy controls was genotyped for the -1195 A→G (rs689466) 
and -765G→C  (rs20417) polymorphisms. Distribution of genotypes in patients and 
controls were compared and genotype-phenotype interactions were investigated.
The genotype distribution of the -1195A→G polymorphism was not different between 
the patients with CD or UC and the control group. The -765GG genotype was more 
prevalent in CD patients compared to controls with an OR of 1.33 (95% CI 1.04-
1.69, p < 0.05). The -765GC and -765CC genotype carriers showed a tendency to be 
less frequent in patients with CD compared to controls, with ORs of 0.78 (95% CI: 
0.61-1.00) and 0.49 (95% CI 0.22-1.08), respectively. Combining homozygous and 
heterozygous patients with the -765C allele showed a reduced risk for developing 
CD, with an OR of 0.75 (95% CI: 0.59-0.96). In the context of this, the G-1195G-765/A-
1195C-765 diplotype was significantly less common in patients with CD compared to 
controls, with an OR of 0.62 (95% CI: 0.39-0.98). For UC however, such an effect 
was not observed. No correlation was found between COX-2 diplotypes and clinical 
characteristics of IBD. 
In conclusion, the -765G→C polymorphism was associated with a reduced risk for 
developing Crohn’s disease in a Dutch population.
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Introduction
Inflammatory bowel disease (IBD) is an idiopathic, chronic, relapsing auto 
inflammatory disorder of the gastro-intestinal tract. The two major types of IBD 
are Crohn's disease (CD) and ulcerative colitis (UC). Genetic, immunological and 
environmental factors are thought to play a role in the pathogenesis of IBD.1 A 
dysregulated immune response against the intestinal microbiota in genetic susceptible 
individuals has been heavily implicated in the pathogenesis of inflammatory bowel 
disease.2 Therefore, genes involved in inflammatory responses are under investigation 
to look for variants predisposing to IBD.
Cyclooxygenase (COX) is a modifier gene and key enzyme in the conversion of free 
arachidonic acid into prostaglandins and is involved in the regulation of inflammatory 
processes through its products, mainly prostaglandin E2 (PGE2).3 The COX family 
consists of two main isozymes: COX-1 and COX-2. COX-1 is constitutively expressed 
in most cell types, including the mucosal compartment of the gastrointestinal tract, 
and is important for maintaining mucosal integrity, mucosal defence and regulation 
of the mucosal blood flow.4, 5 Being very low expressed in the normal gut mucosa, 
COX-2 expression can be induced by mitogenic and proinflammatory stimuli.5, 6
The relevance of COX-2 in the pathogenesis of IBD has been demonstrated; increased 
expression of COX-2 has been observed in colonic epithelial cells, the myenteric 
plexus and in the medial layer of arteries from patients with active IBD.7–9 In addition, 
a relationship between endoscopic activity of IBD and mucosal COX-2 mRNA levels 
was noticed.10 
Although COX-2 is involved in the regulation of inflammatory processes, it also 
seems to play a physiological role in the defence of the gastric mucosa, as well as 
in the maintenance of gastric mucosal integrity when other defence mechanisms 
are impaired or COX-1 activity is latent.3, 5 Moreover, COX-2 seems to be a major 
contributor to the processes that lead to resolution of inflammation.11 In line with 
this, the use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with 
IBD may be associated with exacerbation of the underlying IBD and gastrointestinal-
related complications.12–14 Overall, these findings suggest that COX-2 has a dual role 
by both initiation as well as resolution of inflammation.
Functional polymorphisms in the COX-2 promoter, being -765G→C (rs20417) and 
-1195A→G (rs689466), may alter the enzyme function of COX-2 by differential 
regulation of COX-2 expression.15 Recently, a study by Østergaard et al. reported 
an association of the -765G→C polymorphism with IBD in a Danish population.16 
Another study from a previous relatively small sample size study performed in the 
Netherlands however, showed no association between these two polymorphisms and 
IBD.17 We therefore investigated the COX-2 -1195A→G and -765G→C polymorphisms 
in relation to the development and clinical severity of IBD in a phenotypically well 
characterized and relatively large IBD cohort of Dutch origin and hypothesized that 
carriers of the -1195A→G and/or -765G→C polymorphisms might be at risk for 
developing IBD.
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Materials and Methods
Patients and controls
This case-control study included 736 patients with inflammatory bowel disease (39% 
men, mean age 45.0 ± 13.9 years), 525 patients with Crohn’s disease (35% men, mean 
age 44.5 ± 13.9) and 211 patients with ulcerative colitis (48% men, mean age 46.1 ± 
14.0) and 973 disease-free controls (43% men, mean age 47.2 ± 16.6 years). All patients 
were of Dutch origin and were recruited from the outpatient clinic of the Radboud 
University Nijmegen Medical Center, the Netherlands. Controls were recruited from 
the Nijmegen area by advertisement in local papers. The clinical characteristics of 
the patients are summarized in tables 7.1 and 7.2. Diagnosis of inflammatory bowel 
disease was based on accepted clinical, endoscopic, radiological and histological 
findings.18 Clinical data of the patients were retrieved by retrospective collection 
from patients’ clinical charts. Phenotypes of the patients were described according 
to age of onset, necessity of surgery, family history of IBD, the occurrence of extra-
intestinal manifestations and maximum extent of disease according to the Vienna19 
and Montreal20 classifications for Crohn’s disease and ulcerative colitis respectively. 
Information on development of dysplasia and colorectal cancer (CRC) in our 
patient cohort was retrieved using PALGA, the nationwide network and registry of 
histopathology and cytopathology in the Netherlands.21
The ethical committee of region Nijmegen and Arnhem reviewed and approved the 
protocol under number CWOM-nr 9804-0100. Verbal informed consent was obtained 
from each patient before study participation in agreement with the approval and all 
samples were anonymized. Since research data were collected anonymously, at least 
verbal informed consent was needed according to national regulations. Therefore, no 
written informed consent procedure was introduced at time of data collection.
Genotyping
Whole blood from patients and healthy controls was obtained by venapuncture in 
sterile vacutainer tubes, anti-coagulated with EDTA and stored at -20°C until use. 
DNA from patients and controls was isolated from whole blood using the Pure 
Gene DNA isolation kit, according to the instructions of the manufacturer (Gentra 
Systems, Minneapolis, MN) and stored at 4°C. Genotypes of the COX-2 -1195A→G 
polymorphism was determined by polymerase chain reaction (PCR)-based restriction 
fragment length polymorphism assays, as described by Zhang et al.15 The COX-2 
-765G→C polymorphism was determined by a dual-color discrimination assay using 
the iCycler iQ Multicolour Real-Time Detection System (Bio-Rad Laboratories, 
Hercules, CA), as described by Peters et al.22
Statistical analysis
Baseline and clinical characteristics were analysed with standard descriptive statistics. 
The observed genotype frequencies were tested for deviation from the Hardy-
Weinberg equilibrium. 
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Estimates of linkage disequilibrium (LD) between SNPs were determined by 
calculating pair-wise D2 and r2 statistics in unrelated individuals, using Haploview. 
Differences in -1195A→G and -765G→C genotype distributions between the 
patient and control groups were determined by χ2 analysis. Odds ratios (ORs) with 
95% confidence interval (95% CI) were calculated for genotypes associated with 
predicted normal versus predicted altered enzyme activities (variant genotypes) 
between IBD patients and controls. These analyses were also applied for testing 
of either UC or CD with the control group. Based on the two polymorphisms 
investigated, a diplotype analysis was performed. Diplotypes were compared with 
regard to phenotypical characteristics and comparisons were given as ORs with 95% 
CI. Additionally, we investigated in patients with IBD whether the -1195A→G and 
-765G→C polymorphisms were associated with development of mucosal dysplasia 
or colon cancer. Data analysis was performed using SPSS software (Version 16.0, 
SPSS, Chicago, IL, USA). A p-value of < 0.05 was used as a criterion for statistical 
significance.
Table 7.1 Clinical characteristics of patients 
with Crohn’s disease (n=525)
Characteristics (%)
Age at diagnosis, years 
(SD)
27.1 ± 10.7
Family history  of IBD* 75/272 (27.6)
Disease localization 
Ileal 187 (35.6)
Colonic 127 (24.2)
Ileocolonic 211 (40.2)
Isolated upper disease+ 36 (6.9)
Disease behaviour CD 
Non stricturing, non 
penetrating
176 (33.5)
Stricturing 89 (17.0)
Penetrating 260 (49.5)
Extra-intestinal disease* 161/ 491 (32.8)
Peri-anal disease* 180/ 509 (35.4)
Surgery 320 (61.0)
+Patients could be classified as having disease 
localisation in the upper gastrointestinal 
tract next to ileal, colonic or ileocolonic 
localisation. *Note that data of patients are 
missing
Table 7.2 Clinical characteristics of 
patients with Ulcerative Colitis (n=211)
Characteristics (%)
Age at diagnosis, 
years (SD)
32.9 ± 12.7
Disease localization* 
Proctitis 13/ 203 (6.4)
Left sided 70/ 203 (34.5)
Extended/pancolitis 120/ 203 (59.1) 
Surgery 59 (28.0)
*Note that data of 8 patients are missing
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Results
In this study 736 patients with inflammatory bowel disease, 525 patients with Crohn’s 
disease and 211 patients with ulcerative colitis as well as 973 healthy controls were 
included. No statistical significant differences were observed between patients with 
IBD and controls regarding age and gender. However when the CD or UC patient 
groups were compared to controls separately, significant more females were present 
in the group with Crohn’s disease (p < 0.01).
Distribution of the -1195 and -765 COX-2 genotypes in both patient and control groups 
fitted the Hardy Weinberg equilibrium; for the -1195 COX-2 genotypes, p-values of p = 
0.14, p = 0.17 and p = 0.99, for the patients with Crohn’s disease, ulcerative colitis and 
controls were found; whereas corresponding p-values for the -765 COX-2 genotypes 
were p = 0.64, p = 0.26 and p = 0.87, respectively. As been reported before by others,15, 
17, 23 both SNPs were found to be in strong linkage disequilibrium (D’ = 1, r2 = 0.05).
Genotype distribution and association with inflammatory bowel disease
The distribution of the -1195 and -765 COX-2 genotypes as found in patients with 
IBD and controls is given in table 7.3. The -1195 genotype distribution was not 
different between the patients with Crohn’s disease, ulcerative colitis, or all IBD 
patients taken together in comparison with the control group. However, the -765 
genotype distribution showed a tendency towards a significant difference between 
patients with Crohn’s disease and controls, with the -765GC and -765CC genotypes 
being less prevalent in patients, with ORs of 0.78 (95% CI 0.61-1.00, p < 0.05) and 
0.49 (95% CI 0.22-1.08) respectively and the -765GG genotype being more prevalent 
in patients (OR 1.33, 95% CI 1.04-1.69, p < 0.05). No differences were found between 
patients with ulcerative colitis and controls. Combining homozygous (-765CC) and 
heterozygous (-765GC) patients bearing the -765C allele, showed a reduced risk for 
developing Crohn’s disease in this group (OR = 0.75, 95% CI 0.59-0.96, p < 0.05). 
The effects of the two COX-2 polymorphisms were then studied in the context of 
diplotypes. Six diplotypes were identified, with the A-1195G-765/A-1195G-765 diplotype 
being the most prevalent in both patients and controls (table 7.4). The G-1195G-765/
A-1195C-765 diplotype was significantly less frequent in patients with Crohn’s disease 
compared to controls with an OR of 0.62 (95% CI 0.39-0.98, p < 0.05).
Correlation of the COX-2 diplotypes with clinical characteristics of IBD patients
Additionally, clinical characteristics of patients with Crohn’s disease and ulcerative 
colitis were studied in the context of diplotypes in which the most common A-1195G-
765/A-1195G-765 diplotype served as reference. No significant association between the 
COX-2 diplotypes and clinical characteristics of either Crohn’s disease or ulcerative 
colitis was found (tables 7.5 and 7.6). When data were corrected for age and gender, 
no significant changes in data were observed.
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COX-2 polymorphisms and the risk for developing dysplasia and colon cancer in 
patients with inflammatory bowel disease
The PALGA search regarding dysplasia and colon cancer in our IBD cohort 
demonstrated that 29 patients (15 patients with CD and 14 patients with UC) 
developed mucosal dysplasia, which is regarded as a pre-malignant phase of CRC. 
Furthermore, in the CD cohort 7 patients with CRC were identified; 4 having the 
A-1195G-765/A-1195G-765 diplotype and 3 having the G-1195G-765/A-1195G-765 diplotype. In 
the UC cohort, no patients were identified who developed CRC. When tested, no 
association was found between the COX-2 diplotypes and the development of colonic 
dysplasia or cancer (tables 7.5 and 7.6).
Discussion
This study was performed to determine the possible modulating effect of the COX-2 
-1195 A→G and -765G→C polymorphisms on the risk of developing inflammatory 
bowel disease. Carriers of the -765C allele showed a reduced risk for developing CD. 
This result suggests that the -765G→C change induces an altered enzyme expression 
and enzyme activity with potential anti-inflammatory consequences.
Studies regarding the functional consequences of the -765G→C polymorphism in 
the COX-2 promoter are conflicting. Therefore, the (physiological) consequences 
of our findings are difficult to interpret. First of all, the -765C-containing COX-2 
promoter was reported to drive lower reporter gene expression in vitro compared 
to the -765G-containing counterpart.15, 24 Furthermore, serum prostaglandin E2 
(PGE2) concentrations of renal transplant recipients patients with the GG genotype 
were significantly higher than PGE2 concentrations from patients with the C 
allele.25 Subsequent work from Zhang and coworkers showed that the -765G→C 
polymorphism creates a binding site for nucleophosmin (NPM) and phosphorylated 
nucleophosmin (p-NPM), which acts as an inhibitor of COX-2 transcription.26 The 
-1195 A→G polymorphism creates a c-MYB binding site, which can activate COX-2 
expression, and displays a higher promoter activity.15
In normal colorectal mucosa COX-2 expression is enhanced in patients with IBD 
when compared to subjects with normal colonoscopy.27 Taken together in light of 
our results, this would imply that low levels of COX-2 are associated with an reduced 
risk for developing CD. In vitro however, when cells were treated with smoking 
condensate, the -765C-containing promoter exerted a significantly higher reporter 
gene expression compared to the -765G-containing counterpart.26 Besides this, 
Szczeklik and co-workers reported an increased production of prostaglandin E2 and 
D2 (PGE2 and PGD2) by monocytes obtained from female patients with asthma who 
were homozygous for the -765C variant of the COX-2 gene.28, 29 In the context of 
IBD, PGE2 appears to play a dual role. In IBD, PGE2 production is increased30 and 
in an experimental model of IBD high levels of PGE2 exacerbate inflammation.31 
On the other hand, PGE2 signaling is required for suppressing colitis symptoms and 
protecting mucosal damage by maintaining the integrity of the epithelial intestinal 
wall, presumably through the enhancement of epithelial survival and regeneration.32
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Furthermore, PGE2 has been recently identified to promote naive T cell differentiation 
to IL-17 – producing T helper (Th17) cells, a subset of T helper cells which have been 
implicated as potent effector cells in IBD.33
Several limitations of our study should be noticed. First of all we were not able to 
retrieve the smoking status of our patients and controls, as Zhao et al.26 demonstrated 
an effect of smoking on the expression of the -765G→C polymorphism. Secondly, the 
effect of the COX-2 -1195A→G and -765G→C polymorphisms on colonic mucosal 
COX-2 expression and/or PGE2 production in patients with IBD is unknown. 
However regardless of these data, the functional consequences of PGE2 in IBD still 
remains conflicting as pointed out above.
The results of our study are in conflict with a Danish case control study by Østergaard 
et al. who identified that carriers of the homozygous -765CC variant had a relatively 
high risk for developing CD as well as UC, with an OR of 2.78 (95% CI = 1.33-5.88, p 
= 0.006) and 2.63 (95% CI = 1.35-5.26, p = 0.005) respectively.16 The -765CC variant 
however is very rare in our population of IBD patients (n = 17, 2.3%) and controls 
(n = 28, 2.9%) as is the case in another Dutch study by Cox et al. in which (2.4%) of 
the patients and (2.4%) of the controls had this variant.17 In the study of Cox et al., 
no significant association between the -1195A→G and -765G→C polymorphisms and 
IBD was found, although the number of patients with IBD involved (n = 291) was 
rather small. However, a recent subsequent study from the Danish group of Østergaard 
and co-workers extended the original data with data from Scottish IBD patients and 
showed no association any more with the -765G→C polymorphism and development 
of IBD.34 The differences between our results and the Danish and Scottish findings 
could be attributed to the fact that the genetical contribution to the etiology of IBD 
in the northern part of Europe differs from central Europe. Mutations in the three 
common CD-associated variants of CARD15, R702W, G908R and 1007fsinsC, are 
relatively rare in Northern countries including Denmark and Scotland, while the 
mutation frequencies are relatively high in Central Europe.35
As stated before, patients with IBD show increased expression of COX-2 in the 
gastrointestinal tract.7, 8, 10, 27 This increased expression of COX-2 has also been observed 
in gastrointestinal adenocarcinomas and in UC-associated neoplasia.36, 37 Additionally, 
the COX-2 -1195A→G and -765G→C polymorphisms were demonstrated to influence 
the expression of COX-2 and confer a risk for developing (adeno)carcinomas in the 
gastrointestinal tract.15, 38, 39 Chronic intestinal inflammation-associated colorectal 
carcinogenesis is thought to occur via a stepwise progression beginning with 
epithelial hyperplasia, leading to various grades of dysplasia, adenoma, and then to 
adenocarcinoma.40 We investigated whether or not an association could be found 
between the COX-2 polymorphisms and dysplasia or CRC in patients with IBD. Due 
to the restricted number of patients who developed dysplasia or CRC, no differences 
could be observed.
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Conclusion
Subjects with the -765C allele showed a reduced risk for developing CD. No 
correlation could be found between the COX-2 diplotypes and clinical characteristics 
of IBD patients and the development of colonic dysplasia or cancer. Further studies 
are required to confirm the association we found and efforts should be made to 
unravel the role of COX-2 and its derived prostaglandins in the pathogenesis of IBD.
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Summary
Infliximab is a monoclonal antibody against tumour necrosis factor α (TNF-α) and 
well incorporated in the treatment of patients with auto-inflammatory disorders such 
as inflammatory bowel disease (IBD). Blocking a cytokine central to the inflammatory 
response might lead to adverse events secondary to impaired immunity such as 
serious infections and even development of malignancies. 
The primary aim of this thesis, as described in chapter 1, was to determine a 
safety profile of infliximab. To this end in chapter 2A we evaluated serious events, 
defined as any unfavourable event since the start of infliximab treatment, leading 
to hospitalization, malignancies and death, in a cohort of IBD patients. This cohort 
included 147 patients receiving 1924 infusions with infliximab (median of 10 per 
patient) over a median follow-up period of 59 months. Patients were followed for a 
total of 674 patient years. The rate of acute infusion reactions to infliximab (8%) seen 
was comparable with reported rates in other studies. Sixty-one percent of all patients 
were hospitalised after start of infliximab during follow-up. In 14% of all patients, the 
main reason for hospitalization was an infection which was considered at least possibly 
related to the use of infliximab. Nine patients developed malignancies and subgroup 
analysis, comparing patients with and without malignancies, showed a significant 
difference in duration of disease. A causal relationship between the use of infliximab 
and the development of solid tumours could not be made; the malignancies seem to 
be more related to underlying disease than to the use of infliximab. However, these 
malignancies developed at a relative young age. This indicates that careful monitoring 
of patients with IBD for signs which could be attributable to a malignancy, is necessary 
to detect serious events in an early stage. 
We also commented on another study evaluating the long term safety of infliximab, 
in chapter 2B, and compared their results with other studies published in the same 
year (2009). Focusing on the development of malignancies, we emphasized the need 
of long term follow-up. A Belgian cohort study compared IBD patients treated with 
infliximab with patients not receiving any biological therapy and found no differences 
in terms of mortality, infection rates, and malignancies.1 Infliximab therapy seems to 
be safe in the long term, although thorough follow-up evaluation of patients with IBD 
for the development of malignancies is warranted. This typically in patients receiving 
concomitant immunosuppressive therapy.2 
Optimal monitoring of biological therapies is of major clinical importance. In clinical 
practice,  monitoring vital signs (.e. blood pressure, pulse, temperature) is routinely 
performed with infliximab administration. This management strategy is based on 
the fact that infliximab may cause acute severe infusion reactions with associated 
signs and symptoms which most commonly include fever, chest pain, hypotension/ 
hypertension, or dyspnea.3 In chapter 2C we evaluated the clinical value of a strategy 
that monitored vital signs. Scheduled monitoring of vital signs was of no value to 
predict the development of acute infusion reactions. 
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Therefore, scheduled measurement of vital signs during infliximab infusions is 
probably unnecessary.
In chapter 3 we described the results of a multidisciplinary consensus meeting 
regarding current guidelines and consensus statements on the use of infliximab for 
auto-inflammatory disorders. Several topics (i.e. dosage of infliximab, monitoring of 
vital signs, use of concomitant medication and loss of response) were discussed and 
shortcomings in guidelines and consensus statements concerning these topics were 
identified. There are dosing schedules for different indications. National and internal 
guidelines lack advice how and when to choose for dosage adjustment or frequency 
intensification in case of loss of response. The high prevalence of co-morbidities in 
patients with auto inflammatory disorders, such as IBD,4,5 plus the shared knowledge 
of specialists treating these patients with biological therapies, require a multi-
disciplinary approach. In our current age of ongoing specialisation this is necessary 
to keep a multifaceted view on the use of biological agents like infliximab.
Infliximab-induced hepatotoxicity is reported in several case reports of IBD patients 
and a direct hepatotoxic effect has been suggested. In chapter 4 we evaluated the in 
vitro toxicity of infliximab and compared this toxicity with the in vitro toxicity of 
immunosuppressants used in the treatment of IBD (thiopurines and methotrexate). 
There was no direct hepatotoxic effect of infliximab, even with increasing 
concentrations up to 5mg/ml. 
The second part of this thesis dealt on identifying genetic susceptibility factors 
possibly associated with IBD. In chapter 5 we tested the hypothesis that a functional 
polymorphism in UGT1A1, which is associated with hyperbilirubinemia, is associated 
with lower disease susceptibility to, and disease behavior within, IBD. Furthermore, 
we investigated a possible pharmacogenetic relationship between UGT1A1*28 and 
thiopurine side effects. The cohort consisted of 751 patients (209 patients with 
ulcerative colitis 542 patients with Crohn’s disease), and 930 healthy controls. Patients 
and controls were genotyped for the UGT1A1*28 promoter polymorphism. Patients 
with Crohn’s disease carried the UGT1A1*28 homozygous genotype significantly less 
often compared to the control group, with an odds ratio of 0.64, 95% CI: 0.42-0.98. 
This suggests that the homozygous state of the UGT1A1*28 polymorphism protects 
against Crohn’s disease. We suggest that this results from the anti-oxidant capacity of 
bilirubin. 
Dectin-1 is involved in the recognition of the fungal component β-glucan and 
amplifies pro-inflammatory cytokine production. An early stop codon polymorphism 
(c.714T>G) in DECTIN-1 results in a loss-of-function (p.Y238X) and impaired 
cytokine responses. In patients with IBD, we observed that dectin-1 expression is 
elevated on macrophages, neutrophils, and other immune cells involved in the 
inflammatory reaction in IBD, as described in chapter 6. 
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We additionally genotyped genomic DNA of 778 patients with Crohn’s disease, 
759 patients with ulcerative colitis and 772 healthy controls for the c.714T>G 
polymorphism. However, no statistically significant difference in DECTIN-1 
c.714T>G allele frequencies was observed between IBD patients and healthy controls.
Cyclooxygenase-2 (COX-2) is a key enzyme involved in the conversion of arachidonic 
acid into prostaglandins and mainly induced at sites of inflammation in response 
to pro-inflammatory cytokines. Patients with IBD show increased expression of 
COX-2 in the gastrointestinal tract, which has also been observed in gastrointestinal 
adenocarcinomas and in ulcerative colitis-associated neoplasia. In chapter 7 we 
determined the possible modulating effect of the functional COX-2 -1195 A→G 
and -765G→C polymorphisms on the risk of IBD. A recent study from Denmark 
indicated that carriers of the COX-2 -1195 A→G variant allele had increased risk 
of ulcerative colitis.6 In our cohort, no such an effect could be seen. However, the 
-765GG genotype was more prevalent in patients with Crohn’s disease compared 
to controls with an odds ratio (OR) of 1.33 (95% CI 1.04-1.69, p < 0.05). Efforts 
should be made to unravel the role of COX-2 and its derived prostaglandins in the 
pathogenesis of IBD.
Future perspectives
Safety assessment of therapies in inflammatory bowel disease
Although randomized controlled trails (RCTs) are the golden standards for studying 
efficacy, in studying safety aspects of medical treatment their use is limited by strict 
inclusion criteria and relatively short follow-up periods.7 The ongoing long-term 
follow-up via registries is important in this respect.8 Recently, the European League 
Against Rheumatism reported on elements to consider when establishing, analyzing 
and reporting safety data of biologics registers in rheumatology.9 Most of these 
points also apply for safety analysis in patients with IBD. First of all, sample size is 
of major importance. Safety assessment requires large cohorts due to the relatively 
low background rates of serious adverse events. Furthermore, there should be clear 
reporting of study design and methodological techniques in order to be able to 
compare the results of these registries. A meaningful comparator (i.e. an unexposed 
cohort) must be included, which should be as similar as possible to the exposed 
group and potential biases should be noticed. Potential bias includes the higher 
rate of co-morbidity observed in referral centers together with the fact that clinical 
decisions will influence which patients receive more extensive treatment, potentially 
introducing ‘channeling bias’. 
The Dutch ‘Parelsnoer’ project, a biobank project in which all eight medical university 
centers in the Netherlands participate, might function as a template for a large clinical 
practice registry which enables to study long term safety of various treatments given 
in IBD. In this biobank project, standardized clinical data of IBD patients is obtained 
prospectively and integrated with standard molecular data from biomaterials taken. 
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This approach will enable us to collect a large dataset on patients with distinct clinical 
characteristics. 
Predictors of effects and adverse events
The treatment of patients with IBD can be very challenging. First of all, although 
the natural history of IBD progressively leads to the development of complications 
in approximately two-thirds of Crohn’s disease patients and less than one-third of 
ulcerative colitis  patients, the clinical course of the disease varies greatly among 
patients.10 Therefore, sensitive and specific markers to predict disease course and to 
identify those patients with an aggressive and progressive disease course that would 
benefit from early use of biologics to prevent future complication and surgery are 
necessary. Some clinical factors have been associated with a disabling course of 
disease including disease location (terminal ileum), disease behavior (structuring 
and penetrating behavior), age at diagnosis (< 40 years), the presence of perianal 
disease and the initial requirements for steroids.11,12 Furthermore, several predictive 
factors for successful response to anti TNF therapy in Crohn’s disease have been 
identified. Early luminal Crohn’s disease, a high CRP, and high trough concentrations 
of infliximab have been associated with more durable maintenance of clinical 
response.13 On the other hand, the presence of antibodies to infliximab (ATI) as a 
marker of immunogenicity, have been associated with an increased risk of infusion 
reactions and a reduced duration of response.14-16 These observations however, have 
been challenged in a systematic review stating that a more relevant measure than ATIs 
is likely to be measurement of circulating drug concentration since measurement of 
ATIs is so dependent on analytical technique, timing of sampling, dosing regimen, 
circulating drug, concomitant therapy, and the individual patient.17 Additionally, 
advanced age appears to be an independent risk factor for severe infections and 
mortality in patients given anti-tumor necrosis factor therapy for IBD.18 
The use of a large clinical registry as mentioned before, would be of major importance 
to identify risk factors for serious outcomes in drug treatment. Since biological 
therapies are indicated for various auto inflammatory disorders, this identification 
process will require a multidisciplinary approach. Currently, the ‘Parelsnoer’ project 
includes a registry on IBD as well on rheumatoid arthritis. Since biomaterials are 
also obtained in this project, efforts should be made to unravel genetic susceptibility 
factors for efficacy and/ or side effects of biological treatment for various indications. 
In the future, this might enable clinicians to select the appropriate therapy for patients 
and to predict responses to these therapies. 
Genetic susceptibility and IBD
In our studies we used a mechanistic approach, in which known functional 
polymorphisms were tested in IBD patients. However, in the era of genome wide 
association studies (GWAS), many new genomic regions containing IBD risk factors 
have been identified with much more statistical power. Knowledge on the functional 
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consequences of these genetic variants however is scarce. Additional studies are 
therefore needed to investigate the biological and cellular pathways involved. 
Most of the alleles identified by GWAS are relatively common (allele frequencies 
>5%) and all these loci together explain less than 25% of the overall predicted 
genetic heritability in Crohn’s disease.19 Polymorphisms that have a stronger effect 
on disease development might be maintained at a lower frequency in the population 
(uncommon alleles) through negative selection, because they reduce reproductive 
fitness. The identification of these uncommon alleles might be greatly facilitated by 
new techniques as whole-exome and whole-genome sequencing. Recently, successful 
clinical application of whole-exome sequencing was shown in a child with intractable 
IBD, having a hemizygous missense mutation in the X-linked inhibitor of apoptosis 
gene.20 These new sequencing technologies can also be used to catalogue the resident 
microflora at distinct body sites, and studying correlations between specific diseases 
and the composition of the microbiome.21 
Furthermore, a full understanding of IBD requires capturing much of the genetic 
variation across the human population (i.e. genetic studies on IBD should also 
include non Caucasian populations), which will increase the power of GWAS. Also, 
the annotation and correlation of genomic information with high-quality phenotypic 
data is of major importance.22 In the (near) future, this might lead to personalized 
medicine, tailored to individual patients.
Finally, to study the links between biological and environmental factors in complex 
diseases, such as IBD, it will be necessary to conduct suitably large (several hundred 
thousand people) prospective cohort studies with GWA genotyping, and reproducible 
reliable exposure measures at baseline.22,23 Although the costs are high, several 
prospective cohorts for studying complex diseases have been established,24-26 which 
will definitely enhance our understanding of the gene-environmental interplay. 
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Samenvatting
Infliximab is een monoklonaal antilichaam gericht tegen tumor necrosis factor alpha 
(TNF-α). Het middel speelt een belangrijke rol in de behandeling van patiënten met 
auto-inflammatoire ziekten, zoals inflammatoire darmziekten (IBD). Het blokkeren 
van een belangrijk cytokine voor de inflammatoire respons kan leiden tot bijwerkingen 
die secundair zijn aan een verminderde weerstand, zoals ernstige infecties en zelfs 
het ontwikkelen van kwaadaardige tumoren (maligniteiten). Het primaire doel van 
dit proefschrift, zoals beschreven in hoofdstuk 1, was om het veiligheidsprofiel 
van infliximab te bepalen. In verband hiermee hebben we in hoofdstuk 2A 
gekeken naar de incidentie van ernstige neveneffecten, gedefinieerd als ongunstige 
gebeurtenissen die optraden na start van de behandeling met infliximab, welke leiden 
tot ziekenhuisopname, maligniteiten en overlijden binnen een cohort van IBD 
patiënten. Dit cohort betrof 147 patiënten die in totaal 1924 infusies met infliximab 
ontvingen (mediaan van 10 per patiënt) gedurende een mediane follow-up duur van 
59 maanden. In totaal werden deze patiënten voor 674 patiëntjaren gevolgd. Het 
percentage acute infusiereacties op infliximab (8% van de patiënten) was vergelijkbaar 
met gerapporteerde percentages in andere studies. Gedurende de follow-up duur 
werd 61% van alle patiënten tenminste eenmaal opgenomen in het ziekenhuis. Bij 
14% van alle patiënten was de belangrijkste reden voor ziekenhuisopname een 
infectie die beschouwd werd als ten minste mogelijk gerelateerd aan het gebruik van 
infliximab. Negen patiënten ontwikkelden maligniteiten in de follow-up periode en 
nadere analyse van patiënten met en zonder maligniteiten toonde een significant 
verschil in ziekteduur. Een causaal verband tussen het gebruik van infliximab en de 
ontwikkeling van maligniteiten kon niet worden gelegd. De maligniteiten lijken meer 
gerelateerd te zijn aan de onderliggende ziekte dan aan het gebruik van de infliximab. 
Echter, patiënten ontwikkelden deze maligniteiten op een relatief jonge leeftijd. Dit 
betekent dat zorgvuldige controle van IBD patiënten op tekenen die kunnen worden 
toegeschreven aan een maligniteit nodig is om dit in een vroeg stadium te kunnen 
detecteren. 
In hoofdstuk 2B hebben we commentaar gegeven op een andere studie die de 
langetermijnveiligheid van infliximab heeft geëvalueerd en hebben we de resultaten 
vergeleken met andere studies die in hetzelfde jaar gepubliceerd zijn (2009). Met 
betrekking tot de ontwikkeling van maligniteiten benadrukken we de noodzaak van 
lange termijn follow-up. Een Belgische cohort studie vergeleek IBD patiënten die 
behandeld waren met infliximab met patiënten die geen behandeling met biologicals 
hadden ontvangen en vond geen verschillen in termen van sterfte, infecties en 
maligniteiten.1 Hoewel infliximab een veilige en effectieve therapie lijkt te zijn op 
de lange termijn, is grondige follow-up met betrekking tot de ontwikkeling van 
maligniteiten noodzakelijk bij patiënten met IBD die behandeld worden met immuun 
modulerende therapie. Dit is vooral het geval bij patiënten die gelijktijdig meerdere 
vormen van immunosuppressieve therapie ontvangen.2 
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Optimale monitoring van de therapieën met biologicals is van klinisch belang. 
In de klinische praktijk is het controleren van de vitale functies (bloeddruk, pols, 
temperatuur) geïmplementeerd tijdens het toedienen van infliximab. Deze strategie 
is gebaseerd op het feit dat infliximab acute ernstige infuusreacties kan veroorzaken, 
vaak gekenmerkt door koorts, pijn op de borst, hypotensie of hypertensie en 
kortademigheid.3 In hoofdstuk 2C hebben we de klinische relevantie van een 
strategie die de vitale functies controleert geëvalueerd. Geplande bewaking van 
de vitale functies is niet van waarde om de ontwikkeling van acute infusiereacties 
te voorspellen. Daarom is het routinematig meten van de vitale functies tijdens 
infliximabinfusies niet zinvol. 
In hoofdstuk 3 hebben we de resultaten van een multidisciplinaire 
consensusbijeenkomst over de huidige richtlijnen en consensus statements omtrent 
het gebruik van infliximab bij auto inflammatoire ziekten beschreven. Verschillende 
onderwerpen (waaronder; dosering van infliximab, monitoring van vitale functies, het 
gebruik van co-medicatie en het beleid bij verlies van de respons op infliximab) werden 
besproken en tekortkomingen in de huidige richtlijnen en consensus statements met 
betrekking tot deze onderwerpen werden geïdentificeerd. De verschillende indicaties 
omvatten verschillende doseringsschema’s. In de nationale en interne richtlijnen 
is er weinig advies over hoe en wanneer men dient te kiezen voor aanpassing van 
de dosering of frequentie intensivering in geval van verlies van respons. De hoge 
prevalentie van comorbiditeit bij patiënten met auto inflammatoire ziekten zoals 
IBD,4,5 plus de gezamenlijke kennis van specialisten aangaande de behandeling van 
deze patiënten met biologische therapieën, vereist een multidisciplinaire aanpak. In 
onze huidige tijd van voortdurende specialisatie is het noodzakelijk om een brede 
blik op het gebruik van biologicals zoals infliximab te houden. 
Een aantal case reports maken melding van infliximab geïnduceerde hepatotoxiciteit 
bij patiënten met IBD en een direct hepatotoxisch effect van infliximab is verondersteld. 
In hoofdstuk 4 hebben we de in vitro toxiciteit van infliximab onderzocht en 
vergeleken met de in vitro toxiciteit van immunosuppressiva zoals gebruikt bij de 
behandeling van IBD (thiopurines en methotrexaat). Geen direct hepatotoxische 
effect van infliximab werd waargenomen, zelfs niet bij concentraties tot 5 g / l.
In het tweede deel van dit proefschrift hebben we getracht genetische risico factoren 
die mogelijk geassocieerd zijn met inflammatoire darmziekten te identificeren. 
Daarbij hebben wij ons gericht op functionele polymorfismen en hebben we hun 
potentiële rol in de pathogenese van IBD onderzocht. In hoofdstuk 5 testten wij de 
hypothese dat een functioneel polymorfisme in UGT1A1, dat wordt geassocieerd met 
hyperbilirubinemie, geassocieerd is met een lager risico op, en ander ziektegedrag 
binnen, IBD. Verder onderzochten we een mogelijke farmacogenetische relatie tussen 
UGT1A1*28 en thiopurine bijwerkingen. Het cohort bestond uit 751
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patiënten (209 patiënten met colitis ulcerosa en 542 patiënten met de ziekte van 
Crohn) en 930 gezonde controles. Patiënten en controles werden gegenotypeerd 
voor het UGT1A1*28 promoter polymorfisme. Binnen het cohort van patiënten 
met de ziekte van Crohn waren er significant minder dragers van het UGT1A1*28 
homozygote genotype in vergelijking met de controlegroep met een odds ratio van 
0.64, 95% betrouwbaarheidsinterval: 0.42-0.98. Dit suggereert dat de homozygote 
toestand van het UGT1A1*28 polymorfisme beschermt tegen de ziekte van Crohn. 
Mogelijk vloeit dit voort uit de antioxidantcapaciteit van bilirubine. 
Dectine-1 is betrokken bij de herkenning van de schimmelcomponent β-glucan en 
versterkt de pro-inflammatoire cytokine productie. Een stop codon polymorfisme 
(C.714T>G) in DECTINE-1 leidt tot een verlies van functie (p.Y238X) en verminderde 
cytokine productie. Bij patiënten met inflammatoire darmziekten hebben we 
vastgesteld dat de dectine-1 expressie verhoogd is in macrofagen, neutrofielen en 
andere immuun cellen die betrokken zijn bij de ontstekingsreactie, zoals beschreven 
in hoofdstuk 6. Verder hebben wij het DNA van 778 patiënten met de ziekte van 
Crohn, 759 patiënten met colitis ulcerosa en 772 gezonde controles gegenotypeerd 
voor het c.714T>G polymorfisme. Er werd echter geen statistisch significant verschil 
in DECTINE-1 c.714T>G allel frequenties waargenomen tussen IBD patiënten en 
gezonde controles.
Cyclooxygenase-2 (COX-2) is een belangrijk enzym dat betrokken is bij de 
omzetting van arachidonzuur in prostaglandines. COX-2 wordt vooral geïnduceerd 
in ontstekingsgebieden in reactie op pro-inflammatoire cytokines. Patiënten met 
IBD vertonen een verhoogde expressie van COX-2 in het maag-darmkanaal en dit 
is tevens waargenomen in gastro-intestinale adenocarcinomen en colitis ulcerosa 
geassocieerde neoplasie. In hoofdstuk 7 hebben we het mogelijke modulerende effect 
van de functionele COX-2 -1195 A → G en -765G → C polymorfismen op het risico 
op inflammatoire darmziekten bepaald. Een recente studie uit Denemarken gaf aan 
dat dragers van de COX-2 -1195 A → G allel variant een verhoogd risico hebben op 
colitis ulcerosa.6 In ons cohort zagen wij een dergelijke effect niet. Echter,  het -765GG 
genotype werd vaker gezien bij patiënten met de ziekte van Crohn in vergelijking met 
gezonde controles met een odds ratio van 1.33 (95% betrouwbaarheidsinterval: 1.04-
1.69, p <0.05). Verder onderzoek naar de rol van COX-2 en de daarvan afgeleide 
prostaglandines in de pathogenese van IBD is noodzakelijk. 
Toekomstperspectieven
Veiligheidsanalyse van therapieën voor inflammatoire darmziekten
Hoewel gerandomiseerde gecontroleerde trails (RCT’s) de gouden standaard zijn 
voor het bestuderen van de effectiviteit van een geneesmiddel, zijn deze studies door 
strikte inclusiecriteria en de relatief korte follow-up periodes beperkt bruikbaar 
voor het bestuderen van de veiligheid van geneesmiddelen.7 Met betrekking tot het 
bestuderen van de veiligheid zijn langdurende follow-up databases van belang.
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Recent heeft de European League Against Rheumatism gerapporteerd welke 
elementen men dient te overwegen bij het vaststellen, analyseren en rapporteren 
van de veiligheid van biologicals binnen deze databases in de reumatologie.9 De 
meeste van deze punten zijn ook van toepassing voor de analyse van de veiligheid 
van biologicals bij patiënten met IBD. Allereerst is de steekproefomvang van 
groot belang. Veiligheidsbeoordeling vereist grote cohorten door de relatief lage 
incidentie van ernstige bijwerkingen. Bovendien moet er een duidelijke rapportage 
zijn van de onderzoeksopzet en methodologische technieken om de resultaten van 
deze databases te kunnen vergelijken. Eveneens dient er een patiëntencohort ter 
vergelijking te worden opgenomen (dat wil zeggen een cohort patiënten dat het 
middel niet heeft gekregen), welke zoveel mogelijk gelijk is aan de behandelde groep. 
Mogelijke vormen van ‘bias’ dienen te worden opgemerkt. Potentiële bias omvat 
de verhoogde co-morbiditeit zoals waargenomen in verwijscentra, alsmede het feit 
dat de klinische toestand beïnvloedt welke patiënten een uitgebreidere behandeling 
krijgen, waardoor mogelijk ‘channeling bias’ wordt ingevoerd. 
Het Nederlandse ‘Parelsnoerproject’, een biobankproject waaraan alle acht medische 
universitaire centra in Nederland deelnemen, kan fungeren als een sjabloon voor een 
grote klinische praktijkdatabase die het mogelijk maakt om de langetermijnveiligheid 
van de gegeven verschillende behandelingen van IBD te bestuderen. In dit 
biobankproject worden gestandaardiseerde klinische gegevens van IBD patiënten 
prospectief verkregen en geïntegreerd met moleculaire gegevens die afkomstig zijn 
van de afgenomen biomaterialen. Deze aanpak zal ons in staat stellen een grote 
dataset van patiënten te verzamelen met duidelijke klinische kenmerken.
Voorspellers van effecten en bijwerkingen
De behandeling van patiënten met inflammatoire darmziekten kan zeer uitdagend 
zijn. Hoewel het natuurlijk beloop van IBD geleidelijk leidt tot de ontwikkeling van 
complicaties bij ongeveer tweederde van patiënten met de ziekte van Crohn en bij 
minder dan een derde van patiënten met colitis ulcerosa, varieert het klinische verloop 
van de ziekte sterk.10 Daarom zijn sensitieve en specifieke markers noodzakelijk 
om het ziekteverloop te kunnen voorspellen en om patiënten met een agressieve 
en progressieve ziekte te identificeren. Deze patiënten zouden kunnen profiteren 
van een vroeg gebruik van biologicals om toekomstige complicaties en chirurgie te 
voorkomen. Een aantal klinische factoren is geassocieerd met een gecompliceerd 
beloop van de ziekte, zoals ziektelocatie (terminale ileum), ziektegedrag (stricturen 
en fistels), leeftijd bij het stellen van de diagnose (<40 jaar), de aanwezigheid van 
perianale ziekte en vroege noodzakelijkheid van corticosteroiden.11, 12 Daarnaast 
zijn er verschillende voorspellende factoren voor een succesvolle reactie op de anti 
TNF therapie bij de ziekte van Crohn geïdentificeerd. Vroege luminale ziekte van 
Crohn, een hoog CRP en hoge infliximab dalconcentraties zijn geassocieerd met 
een langdurige klinische respons.13 Aan de andere kant is de aanwezigheid van 
antilichamen tegen infliximab (ATI) geassocieerd met een verhoogd risico op
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infusiereacties en een verminderde responsduur.14-16 Deze waarnemingen zijn 
echter betwist in een systematische review. Hierin werd gesteld dat het bepalen van 
circulerende geneesmiddel-concentraties zeer waarschijnlijk relevanter is dan ATI 
aangezien de meting van ATI sterk afhankelijk is van de analyse techniek, het moment 
van monsterafname, de dosering, het circulerende geneesmiddel, de gelijktijdige 
behandeling met andere geneesmiddelen en de individuele patient.17 Verder blijkt 
gevorderde leeftijd nog een onafhankelijke risicofactor te zijn voor ernstige infecties 
en mortaliteit bij patiënten met inflammatoire darmziekten die behandeld worden 
met anti-TNF therapie.18
Zoals eerder vermeld is het gebruik van een grote klinische database van groot belang 
om risico’s op ernstige gevolgen bij behandeling met geneesmiddelen te identificeren. 
Aangezien de biologische therapieën zijn geïndiceerd voor diverse auto inflammatoire 
aandoeningen, zal dit identificatieproces een multidisciplinaire aanpak vereisen. Op 
dit moment omvat het Parelsnoerproject zowel een database voor inflammatoire 
darmziekten als voor reumatoïde artritis. Omdat in dit project tevens biomaterialen 
worden verkregen, moeten er inspanningen worden geleverd om voor de verschillende 
indicaties genetische factoren te ontdekken die de werkzaamheid en/of bijwerkingen 
van de biologische behandeling beïnvloeden. Dit zal het voor clinici in de toekomst 
mogelijk maken om de juiste therapie voor de juiste patiënt te selecteren en zal hen 
helpen om reacties op deze therapieën te voorspellen.
Genetische vatbaarheid en IBD
In onze studies hebben wij gebruik gemaakt van een mechanistische benadering, 
waarbij bekende functionele polymorfismen bepaald zijn bij patiënten met IBD. 
Echter, in het huidige tijdperk van genoom wijde associatie studies (GWAS) zijn 
er veel nieuwe IBD risico gengebieden geïdentificeerd met een veel grotere mate 
van statistische zekerheid. Kennis van de functionele gevolgen van deze genetische 
varianten is echter schaars. Aanvullende studies zijn daarom nodig om de betrokken 
cellulaire en biologische mechanismen te onderzoeken. 
De meeste allelen die door GWAS geïdentificeerd zijn komen relatief vaak voor (allel 
frequenties > 5%) en al deze loci samen verklaren minder dan 25% van de totaal 
voorspelde genetische heritabiliteit van de ziekte van Crohn.19 Polymorfismen die 
een groter effect hebben op ziekteontwikkeling kunnen door negatieve selectie echter 
in een lagere frequentie in de bevolking voorkomen (zeldzame allelen) doordat ze 
de reproductiviteit verminderen. De identificatie van deze zeldzame allelen zou in 
hoge mate worden vergemakkelijkt door nieuwe technieken als exoom sequencing 
en het sequencen van het volledig genoom. Recent was er een succesvolle klinische 
toepassing van exoom sequencing bij een kind met onbehandelbare IBD die een 
hemizygote missense mutatie in het X-linked inhibitor of apoptosis gen bleek te 
hebben.20 Deze nieuwe sequencing technieken kunnen ook gebruikt worden om de 
residentiële microflora van de verschillende lichaamsplekken te identificeren en
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op deze wijze de correlaties tussen specifieke ziekte en de compositie van het 
microbioom te bestuderen.21 Verder is het voor een volledig begrip van IBD vereist 
om de genetische variatie binnen de menselijk populatie te bepalen, wat inhoudt 
dat bij genetische studies binnen IBD ook andere rassen dan het Kaukasische ras 
geïncludeerd moeten worden om zo de power van GWAS te vergroten. Ook het 
beschrijven en correleren van genetische informatie aan gedetailleerde fenotypische 
data is van groot belang.22 In de (nabije) toekomst kan dit leiden tot ‘personalized 
medicine’, toegespitst op de individuele patiënt. 
Ten slotte is het voor het bestuderen van de relaties tussen biologische- en 
omgevingsfactoren binnen complexe ziekten, zoals IBD, nodig om grote prospectieve 
cohort studies (enkele honderdduizenden mensen) uit te voeren met GWA 
genotypering en reproduceerbare betrouwbare expositie op baseline.22, 23 Ondanks de 
hoge kosten zijn er al verscheidene prospectieve cohort studies opgezet om complexe 
ziekten te bestuderen.24-26 Deze studies zullen absoluut ons begrip van gen-milieu 
interactie vergroten. 
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Dankwoord & Curriculum Vitae
Dankwoord
Wanneer ik mijzelf als maatstaf neem voor het lezen van proefschriften, dient er 
bij het schrijven de meeste aandacht besteed te worden aan dit gedeelte van mijn 
proefschrift. Het is dan gelijk ook het lastigste gedeelte om te schrijven omdat je altijd 
mensen tekort zult doen. De volgorde die ik hierbij heb gehanteerd is willekeurig, dus 
zie hier geen tekenen in van meerdere of mindere importantie. 
In de eerste plaats wil ik de patiënten bedanken die hun bloed en gegevens wilden 
afstaan ten behoeve van wetenschappelijk onderzoek. Wanneer zij hun medewerking 
niet hadden verleend, had ik dit proefschrift niet kunnen schrijven. 
Prof. dr. Drenth, beste Joost. Als promotor ben je met name bij het begin en einde van 
het traject betrokken geweest. Dat neemt niet weg dat je altijd interesse hebt getoond 
in zowel het onderzoek als in mij persoonlijk. Ondanks je overvolle agenda nam je 
de tijd om met mij na te denken over toekomstperspectieven en onderzoek. Je door 
meerderen geroemde snelheid van beoordeling van artikelen heeft ook mij versteld 
doen staan. Ik wil je graag bedanken voor het vertrouwen dat je in mij hebt gehad. 
Nadat ik nog geen drie maanden als student-assistent werkzaam was op de afdeling 
MDL, kwam je bij me met het verzoek om promotieonderzoek te komen doen. Ik 
hoop dat ik dit vertrouwen niet heb beschaamd. 
Dr. De Jong, beste Dirk. Jij was mijn begeleider bij het onderzoek. Vanaf het moment 
dat ik eind 2007 bij je binnenkwam na een periode in Canada, ben je bij alles betrokken 
geweest. Alhoewel het soms lastig was om naast je drukke klinische werkzaamheden 
ook nog een jonge onderzoeker aan te sturen, hebben we het samen tot een goed 
einde weten te brengen. Bovendien was ik de eerste promovendus waarbij je als co-
promotor betrokken was, wat ook met zich meebracht dat jij soms ook voor dingen 
kwam te staan waar je nooit eerder mee van doen had. Ik wil je hierbij bedanken voor 
je vertrouwen in mij en voor je persoonlijke betrokkenheid. Helaas had je niet altijd 
tijd, maar als het nodig was maakte je ruimschoots tijd voor mij vrij. Niet alleen voor 
overleg met betrekking tot het onderzoek, maar ook voor gesprekken over verdere 
carrière plannen. Dat heb ik heel erg gewaardeerd. Je bent een echte patiëntendokter 
en dat in de goede zin van het woord. Toen ik voor één project, wat helaas niet zo 
veel vruchten heeft afgeworpen, bij patiënten die infliximab infusen moesten krijgen 
liet weten dat ik voor dr. De Jong werkte, hoorde ik veel positieve verhalen over je 
patiëntencontact. Iets wat binnen de geneeskunde opleiding in het Nijmeegse toch 
als een van de belangrijkste zaken gezien word. Ik hoop dat ik ooit net zo’n goede 
dokter zal worden als jij! 
Prof dr Jansen. Ik herinner me u van college als degene die vertelde dat er twee typen 
dokters zijn. Het meer obsessief compulsief type (het “pieppieppiep-type”), en het 
nuchtere type (“mwah-type”). Daarnaast gaf u het advies: “Het enige wat een dokter 
moet hebben is een pluis-niet pluis gevoel.” Ik ben dit nooit meer vergeten. 
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Helemaal omdat u liet merken dat doktoren ook maar mensen zijn en niet zo hoog 
van de toren moeten blazen als dat soms wel gedaan wordt. Door uw manier van 
doen tijdens college, was het dan ook dat ik eind 2006 met de vraag kwam of u 
mogelijkheden wist voor het doen van onderzoek in het buitenland. Eigenlijk wist 
ik niet goed wat het vakgebied van de MDL nu precies inhield, maar ik dacht: als 
deze man representant is voor de MDL komt het wel goed. Ik heb u van de zijlijn 
meegemaakt toen ik in ‘de kelder’ verbleef en u regelmatig langskwam om onderzoek 
te bespreken of gewoon voor koffie. Gedurende mijn co-schappen besloot u om na 
een heel leven werkzaam te zijn geweest aan de universiteit, de laatste jaren in de 
periferie door te brengen. Ik waardeer uw nuchterheid, kennis en socialiteit.
Dr. Peters, beste Wilbert. Jij was met name belangrijk voor het tweede gedeelte van 
mijn proefschrift. Jouw kennis en precisie hebben ervoor gezorgd dat ik in vrij korte 
tijd een aantal studies kon afronden naast mijn co-schappen. Zonder jouw hulp was 
dit absoluut niet gelukt. Jouw precisie bij het nakijken van mijn manuscripten heb ik 
eveneens als zeer bijzonder ervaren. Niets leek jij over het hoofd te zien, waardoor 
de kwaliteit van een artikel zienderogen vooruit ging. Ook wil ik hierbij nog mijn 
waardering uitspreken dat je ondanks mijn verzoek of je niet mijn co-promotor wilde 
worden, liet weten dit niet te doen omdat je vond dat je daarvoor niet voldoende had 
gedaan. Alhoewel ik dit nog steeds niet met je eens ben, waardeer ik je bescheidenheid. 
Helemaal tegen de achtergrond van de medisch wetenschappelijke wereld waarin 
soms mensen wel zeer gebrand zijn op een co-auteurschap bij een minimale imput. 
Je wijze lessen ten aanzien van onderzoek, managers, management en het ‘Peters 
principle’, zal ik ook niet vergeten!
Ing. Te Morsche, beste Rene. Jij bent een van de stille krachten in het lab. Zonder 
jouw hulp had ik dit proefschrift absoluut niet kunnen afmaken. Jouw snelheid van 
werken en kennis omtrent genetica verbazen me elke keer weer. Wat mij betreft heb 
jij de dr. titel allang verdiend!
Ing. Roelofs, beste Hennie. Ondanks het feit dat je ‘het niet zo op dokters hebt’, 
hebben we na een wat stroef begin een zeer plezierige samenwerking gehad. Onze 
gemeenschappelijk interesse in reizen leidde tot lange conversaties over plekken die 
nog op het verlanglijstje staan om te bezoeken. Jij bent ook degene geweest die mij 
allerhande vaardigheden op het lab geleerd hebt, waarvoor dank. Daarnaast heb je 
mij, als niet ‘onder de rivieren afkomstige’, geleerd om te rikken, iets wat essentieel is 
om in het MDL lab te kunnen functioneren... 
Dr. Van Oijen, beste Martijn. Vooral aan het begin van mijn onderzoek ben jij 
betrokken geweest. Jij leerde mij om kritisch te kijken naar onderzoeksresultaten en 
maakte me wegwijs in de wondere wereld van de statistiek. Ook leerde je mij om 
kritisch te kijken naar mijn onderzoeksvragen en de methoden om deze vragen goed 
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te kunnen beantwoorden. Ik herinner me nog een congres in San Diego, waarbij jij ‘s 
morgens vroeg opstond om onze overhemden te strijken zodat we netjes voor de dag 
zouden komen bij mijn posterpresentatie. Helaas werd Nijmegen en op den duur ook 
Nederland voor jou te klein. Ik wens je alle goeds toe in Los Angeles!
Dr. Dieleman, beste Leo. Jij bent degene geweest die ons in 2007 de mogelijkheid 
bood om een half jaar in jouw lab te komen werken. Naast de plezierige tijd in het 
lab denk ik ook met plezier terug aan het feit dat jij ons meenam om te gaan wild-
kamperen met je gezin. De basis voor mijn proefschrift is bij jou gelegd!
Collega’s van de afdeling interne geneeskunde, in het bijzonder prof. dr. Mihai Netea, 
dr. Leo Joosten en dr. Theo Plantenga. Bedankt voor de prettige samenwerking 
tijdens het dectin-1 stuk. De innovativiteit en kwaliteit van jullie onderzoek blijven 
me verbazen. Het is niet voor niets dat ik binnen en buiten het Radboud geregeld 
hoor spreken over ‘koning Mihai’.
Collega onderzoekers en medewerkers van de afdeling MDL, Bjorn, Loes, Esmé, 
Michelle, Leo, Wim, Serena, Evelyn, Manoe, Jannes, Melissa, Wybrich, Jody. Dank 
voor jullie collegialiteit en gezelligheid!
Ik vond het leuk om langs de zijlijn ook nog een student te mogen begeleiden. Tineke, 
bedankt voor je inzet en enthousiasme!
Studievrienden John, Bert-Jan, Bob, Guus, Jacob. Terwijl jullie bezig waren met 
de co-schappen kon ik alleen maar praten over mijn onderzoek. Dank voor jullie 
belangstelling en vriendschap. Nu een aantal van jullie bezig is met promoveren zijn 
de rollen omgedraaid en praten jullie over onderzoek en ik meer over patiëntenzorg. 
Collega’s reumatologie en dermatologie. De komst van de biologicals heeft laten zien 
dat het voor de behandeling van patiënten met auto-inflammatoire ziekten van belang 
is om buiten je eigen vakgebied te kijken. Door ons gezamelijk project heb ik ook een 
klein kijkje in jullie vakgebied gekregen. Dank voor de constructieve samenwerking. 
Hopelijk kan dit in de toekomst uitgebreid worden met een discipline oversteigende 
monitoring van geneesmiddelen.
Lieve opa en oma Verkade. Bedankt voor de belangstelling die jullie altijd in mij 
hebben getoond, zowel in mij persoonlijk als in studie en onderzoek. Ondanks dat 
jullie aangaven dat het allemaal veel te moeilijk voor jullie was om te onthouden, 
bleven jullie altijd belangstellend naar mijn onderzoek. Ik heb dit erg gewaardeerd!
Lieve oma De Vries. Uw nuchtere kijk op dingen is een verademing in een wereld die 
soms wel eens aan elkaar lijkt te hangen van mensen die zichzelf graag voorop zien 
staan. 
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Lieve pa en ma. Jullie wil ik in het bijzonder bedanken voor het vertrouwen dat jullie in 
mij hebben gehad. Ondanks het feit dat geneeskunde de derde studie was waaraan ik 
begon, hebben jullie mij altijd gesteund in mijn studiekeuze en warme belangstelling 
getoond in mijn onderzoek. Pa, een rancuneuze scheikundeleraar schreef bij mijn 
afscheid van de middelbare school “profielwerkstuk? Een goede pa is het halve werk”, 
ik zou deze uitspraak willen veranderen in “promoveren? Een goede pa is het halve 
werk!” De meest trouwe en enthousiaste volger van mijn prille schreden op het pad 
der wetenschap was u. Ik ben heel dankbaar dat u vandaag hier naast mij staat! 
Lieve Evelien, eindelijk is het zover. Alhoewel mijn onderzoek jouw plannen voor 
vrije avonden en weekenden regelmatig doorkruisten, wil ik je bedanken voor je 
steun. Stiekem dacht je altijd dat het rustiger zou worden, maar het werken in de 
kliniek komt niet met de zogenaamde ‘ambtenaren-tijden’. Ondanks alles hebben we 
het prima samen! Ik hou van je!
Tot slot wil ik de Heere God bedanken die mij de kracht, het verstand en inzicht 
gegeven heeft. Ik sluit me dan ook helemaal aan bij het motto van de universiteit; In 
Dei Nomine Feliciter!
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Hilbert de Vries werd op 11 september 1984 geboren te Veenendaal. Na het behalen 
van zijn VWO diploma in 2002, studeerde hij Werktuigbouwkunde aan de Univer-
siteit Twente. Na het behalen van zijn propedeuse startte hij met de nieuwe oplei-
ding Technische Geneeskunde aan dezelfde universiteit. Na het behalen van zijn 
propedeuse van deze opleiding werd in 2004 de overstap gemaakt naar de studie 
Geneeskunde aan de Radboud Universiteit Nijmegen. In 2007 deed hij in het kader 
van zijn wetenschappelijke stage een 6 maanden durend onderzoek aan de Univer-
sity of Alberta, Edmonton, Canada, naar de effecten van prebiotica (niet verteerbare 
voedingsvezels) op de mate van darmontsteking bij HLA-B27 transgene ratten 
(begeleider dr. L.A. Dieleman). In verband met de wachttijd die hij had voordat 
zijn coschappen begonnen, werkte hij vervolgens onder begeleiding van dr. D.J. de 
Jong als student-assistent op de afdeling Maag-darm-leverziekten van het UMC St 
Radboud. Daarmee werd een begin gemaakt aan het huidige promotieonderzoek 
(promotor prof. dr. J.P.H. Drenth). In 2011 trouwde hij met Evelien, studeerde hij af 
en werd tevens dit promotieonderzoek afgerond. Tijdens zijn co-schappen als ook 
tijdens zijn senior coschap in Biharamulo, Tanzania, kwam hij in aanraking met de 
chirurgie. Dit vakgebied wekte zijn bijzondere interesse op. Hij werkt nu als arts-
assistent niet in opleiding bij de afdeling chirurgie van het St Antoniusziekenhuis te 
Nieuwegein (opleider dr. P.M.N.Y.H. Go). 
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